

ผลของเจลคานามัยซินต่อการบาดเจ็บของเซลล์ประสาทจากสภาวะโพแทสเซียมต่ำ
ในเซลล์ประสาทแทรนดูเฉพาะเลี้ยงจากสมองส่วนซีรีเบลลัมของหนูขาว



นางสาว อรุณี คำดี

สถาบันวิทยบริการ
จุฬาลงกรณ์มหาวิทยาลัย

วิทยานิพนธ์นี้เป็นส่วนหนึ่งของการศึกษาตามหลักสูตรปริญญาเภสัชศาสตรมหาบัณฑิต

สาขาวิชาเภสัชวิทยา ภาควิชาเภสัชวิทยา
คณะเภสัชศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย

ปีการศึกษา 2546

ISBN 974-17-5366-7

ลิขสิทธิ์ของจุฬาลงกรณ์มหาวิทยาลัย

EFFECTS OF GELDANAMYCIN ON LOW POTASSIUM-INDUCED INJURIES
IN CULTURED RAT CEREBELLAR GRANULE CELLS



Miss Arunee Kumdee

สถาบันวิทยบริการ

จุฬาลงกรณ์มหาวิทยาลัย
A Thesis Submitted in Partial Fulfillment of the Requirements
for the Degree of Master of Science in Pharmacy in Pharmacology

Department of Pharmacology
Faculty of Pharmaceutical Sciences
Chulalongkorn University

Academic Year 2003

ISBN 974-17-5366-7

อรุณี คำดี : ผลของgeldanamycinต่อการบาดเจ็บของเซลล์ประสาทจากสภาวะโพแทสเซียมต่ำในเซลล์ประสาทแกรนูลเพาะเลี้ยงจากสมองส่วนซีรีเบลลัมของหนูขาว (EFFECTS OF GELDANAMYCIN ON LOW POTASSIUM-INDUCED INJURIES IN CULTURED RAT CEREBELLAR GRANULE CELLS) อ. ที่ปรึกษา: ผศ. ดร. สุรัชย์ อัญเชิญ, 104 หน้า ISBN 974-17-5366-7

geldanamycin (GA) เป็นสารธรรมชาติกลุ่ม benzoquinone ansamycin antibiotic ที่มีฤทธิ์ต้านมะเร็ง การศึกษานี้ออกแบบเพื่อทดสอบผลป้องกันเซลล์ประสาทที่อาจเป็นไปได้ของ GA ต่อการบาดเจ็บและตายของเซลล์ประสาทแกรนูลเพาะเลี้ยงจากสมองส่วนซีรีเบลลัมของหนูขาว อันเกิดจากสภาวะโพแทสเซียมต่ำ โดยใช้การเมตาบอลิซึมและการอยู่รอดของเซลล์ (วัดโดย MTT reduction และ LDH release) ปริมาณของ glutathione และการเกิด lipid peroxidation เป็นตัวชี้วัดเมื่อ incubate เซลล์ประสาทเพาะเลี้ยงเป็นเวลา 12-72 ชั่วโมงกับ GA ความเข้มข้นต่างๆ (0.01-1.0 μM) พบว่าเกิดผลป้องกันเซลล์ประสาทซึ่งขึ้นกับความเข้มข้นและระยะเวลาที่สัมผัสกับ GA โดยที่ความเข้มข้นต่ำและระยะเวลาสัมผัสที่สั้น GA มีผลน้อยต่อเมตาบอลิซึมของเซลล์ประสาท อย่างไรก็ตามหลังจากสัมผัสกับ GA เป็นเวลา 24-48 ชั่วโมง ที่ความเข้มข้นสูงกว่า 0.05 μM GA มีผลกระตุ้นเมตาบอลิซึมของเซลล์ประสาทอย่างชัดเจน เมื่อเซลล์ประสาทสัมผัสกับ GA เป็นเวลา 24 ชั่วโมง ที่ความเข้มข้นสูงกว่า 0.025 μM จะลดการตายของเซลล์อย่างมีนัยสำคัญ ในขณะที่การอยู่รอดของเซลล์ลดลงเมื่อเซลล์ประสาทสัมผัสกับ GA ที่ความเข้มข้นสูงขึ้นและระยะเวลาที่นานขึ้น จะเห็นได้ชัดว่าผลป้องกันเซลล์ประสาทจะเกิดสูงสุดถ้าเซลล์สัมผัสกับ GA เป็นเวลา 24 ชั่วโมง ที่ความเข้มข้น 0.10 μM

หลังจากสลบเซลล์ประสาทแกรนูลเพาะเลี้ยงจาก medium ซึ่งปราศจากซีรัมและมี K^+ 25 mM (high K^+) มายัง medium ซึ่งปราศจากซีรัมแต่มี K^+ เพียง 5 mM (low K^+) เป็นเวลา 24 ชั่วโมง ปรากฏว่าประมาณ 50% ของเซลล์ประสาทตาย การสัมผัสกับ GA พร้อมกับภาวะ low K^+ เป็นเวลา 24 ชั่วโมงไม่มีผลป้องกันการตายของเซลล์ประสาทดังกล่าว ในขณะที่การสัมผัสกับ GA ที่ความเข้มข้น 0.025-0.10 μM ล่วงหน้าเป็นเวลา 24 ชั่วโมงก่อนสัมผัสกับภาวะ low K^+ เป็นเวลา 24 ชั่วโมง มีผลกระตุ้นการเมตาบอลิซึมของไมโทคอนเดรียและป้องกันการตายของเซลล์ประสาทอย่างมีนัยสำคัญ จากการวิเคราะห์ GSH แสดงว่าปริมาณ GSH ในเซลล์ลดลงเกือบ 40% เมื่อสลบเซลล์ประสาทเพาะเลี้ยงมาอยู่ในภาวะ low K^+ เป็นเวลา 24 ชั่วโมง โดยที่การสัมผัสกับ 0.1 μM GA ล่วงหน้าเป็นเวลา 24 ชั่วโมงสามารถป้องกันการลดลงของ GSH ที่เกิดขึ้นได้อย่างมีประสิทธิภาพ นอกจากนี้การสัมผัสกับ GA ล่วงหน้าดังกล่าวสามารถป้องกันการเพิ่มขึ้นของ lipid peroxidation อันเกิดจากภาวะ low K^+ ได้ โดยสรุปข้อมูลเหล่านี้ชี้แนะว่าการสัมผัสกับ GA ล่วงหน้าอาจป้องกันการตายของเซลล์ประสาทแกรนูลจากภาวะ low K^+ ได้ด้วยการเหนี่ยวนำการสังเคราะห์โปรตีนที่กำกับควบคุมการเมตาบอลิซึมของ GSH และขบวนการ lipid peroxidation

ภาควิชา เกสัชวิทยา

ลายมือชื่อนิสิตร.....

สาขาวิชา เกสัชวิทยา

ลายมือชื่ออาจารย์ที่ปรึกษา.....

ปีการศึกษา 2546

4376611433 MAJOR: PHARMACOLOGY

KEYWORDS: GELDANAMYCIN/CEREBELLAR GRANULE CELLS/LOW POTASSIUM/APOPTOSIS

ARUNEE KUMDEE: EFFECTS OF GELDANAMYCIN ON LOW POTASSIUM-INDUCED INJURIES IN CULTURED RAT CEREBELLAR GRANULE CELLS. THESIS ADVISOR: ASST. PROF. SURACHAI UNCHERN, Ph.D., 104 pp. ISBN 974-17-5366-7

Geldanamycin (GA) is a natural benzoquinone ansamycin class antibiotic which possesses antitumor activity. This study was designed to investigate a suspected and potential neuroprotective effect of GA against K^+ deprivation-induced cell injury and death in primary cultured rat cerebellar granule cells. Cell metabolic activity and viability (assessed by MTT reduction and LDH release), content of glutathione and lipid peroxidation, were used as the measuring endpoints. Exposure of cultured cerebellar granule neurons for 12-72 hr to geldanamycin at different concentrations (0.01-1.0 μM) showed concentration- and exposure time-dependent neuroprotective effects. At low concentrations of GA with short incubation periods, GA showed a little effect on neuronal metabolic activity. After 24-48 hr pre-exposure to GA at concentrations higher than 0.05 μM , GA had a marked effect on neuronal metabolic activity whereas an exposure to very high concentrations and prolonged duration caused reduction in cell survival. With 24 hr pre-exposure to GA at concentrations higher than 0.025 μM , cell death was significantly prevented. Apparently, the maximal magnitude of neuroprotection may be obtained from 24 hr pre-exposure to 0.10 μM GA.

After switching cultured cerebellar granule neurons from a serum medium containing 25 mM K^+ (high K^+) to a serum-free medium containing 5 mM low K^+ (low K^+) for 24 hr, approximately 50% of neurons had loss their viability. Simultaneous exposure with GA and low K^+ for 24 hr did not protect neuronal cell death while pretreatment with 0.025-0.10 μM GA for 24 hr before shifting to low K^+ medium significantly boosted up mitochondrial metabolic activity and prevented neuronal cell death in low K^+ condition. Furthermore, GSH assay revealed that total GSH content was reduced by nearly 40% after switching cultured neurons to low K^+ for 24 hr. Pretreatment with 0.1 μM GA for 24 hr effectively inhibited low K^+ -induced GSH diminution. Moreover, the same pretreatment with GA also prevented an increase in cellular lipid peroxidation after 24-hr exposure to low K^+ . These findings suggest that GA pretreatment may prevent granule cell death by induction of proteins that regulate GSH metabolism and lipid peroxidation.

Department of Pharmacology

Student's signature.....

Field of study Pharmacology

Advisor's signature.....

Academic year 2003

ACKNOWLEDGEMENTS

I would like to express my appreciation to Assistant Professor Dr. Surachai Unchern, my advisor, for his guidance, suggestion, supervision, and encouragement throughout my study.

I also would like to express my sincere gratitude to the committee members: Associate Professor Dr. Pornpen Premyothin, Assistant Professor Pol. Lt. Col. Dr. Somsong Lawanprasert and Associate Professor Dr. Vimolmas Lipipun for their comments and valuable opinions.

I also extend my profound gratefulness to Dr. Khanit Suwanborirux and Miss Sarin Tadtong, Department of Pharmacognosy, for kind provision of geldanamycin for my research work.

I would like to acknowledge my thanks to Department of Biochemistry and Department of Pharmacology, Faculty of Pharmaceutical Sciences, for providing research facilities during my study.

Finally, this thesis will never be accomplished without my family's care and my friends' will power. Thank you for all supports which are essential to my success.

สถาบันวิทยบริการ
จุฬาลงกรณ์มหาวิทยาลัย

CONTENTS

| | Page |
|--------------------------------------|------|
| ABSTRACT (THAI)..... | iv |
| ABSTRACT (ENGLISH)..... | v |
| ACKNOWLEDGEMENTS..... | vi |
| CONTENTS..... | vii |
| LIST OF TABLES..... | viii |
| LIST OF FIGURES..... | x |
| LIST OF ABBREVIATIONS..... | xii |
| CHAPTER | |
| I INTRODUCTION..... | 1 |
| Introduction..... | 1 |
| Objectives..... | 3 |
| II LITERATURE REVIEW..... | 4 |
| Geldanamycin..... | 6 |
| Low potassium induced apoptosis..... | 18 |
| III MATERIALS AND METHODS..... | 20 |
| IV RESULTS..... | 31 |
| V DISCUSSIONS AND CONCLUSION..... | 63 |
| REFERENCES..... | 68 |
| APPENDICES..... | 87 |
| CURRICULUM VITAE..... | 104 |

LIST OF TABLES

| Table | Page |
|-------|--|
| 1 | Effects of geldanamycin on MTT reduction in cultured cerebellar granule neurons |
| 1.1 | 12 hr of incubation..... 88 |
| 1.2 | 24 hr of incubation..... 88 |
| 1.3 | 48 hr of incubation..... 89 |
| 1.4 | 72 hr of incubation..... 89 |
| 2 | Effects of geldanamycin on LDH release in cultured cerebellar granule neurons |
| 2.1 | 12 hr of incubation..... 90 |
| 2.2 | 24 hr of incubation..... 90 |
| 2.3 | 48 hr of incubation..... 91 |
| 2.4 | 72 hr of incubation..... 91 |
| 3 | Time course of low K ⁺ -induced injuries in cultured cerebellar granule neurons |
| 3.1 | MTT reduction assay..... 92 |
| 3.2 | LDH release assay..... 92 |
| 4 | Effects of geldanamycin on low K ⁺ -induced injuries in cultured cerebellar granule neurons (determined by MTT reduction assay) |
| 4.1 | Cotreatment..... 93 |
| 4.2 | Pretreatment with geldanamycin for 6 hr of incubation..... 93 |
| 4.3 | Pretreatment with geldanamycin for 12 hr of incubation..... 94 |
| 4.4 | Pretreatment with geldanamycin for 24 hr of incubation..... 94 |
| 4.5 | Pretreatment with geldanamycin for 48 hr of incubation..... 95 |
| 4.6 | Pretreatment with geldanamycin for 72 hr of incubation..... 95 |
| 5 | Effects of geldanamycin on low K ⁺ -induced injuries in cultured cerebellar granule neurons (determined by LDH release assay) |
| 5.1 | Cotreatment..... 96 |
| 5.2 | Pretreatment with geldanamycin for 6 hr of incubation..... 96 |
| 5.3 | Pretreatment with geldanamycin for 12 hr of incubation..... 97 |
| 5.4 | Pretreatment with geldanamycin for 24 hr of incubation..... 97 |
| 5.5 | Pretreatment with geldanamycin for 48 hr of incubation..... 98 |
| 5.6 | Pretreatment with geldanamycin for 72 hr of incubation..... 98 |

LIST OF TABLES (cont.)

| | | |
|-----|--|-----|
| 6 | Effects of trolox on low K^+ -induced injuries in cultured cerebellar granule neurons (determined by MTT reduction assay) | |
| 6.1 | Cotreatment..... | 99 |
| 6.2 | Pretreatment with trolox for 24 hr of incubation..... | 99 |
| 6.3 | Pretreatment with trolox for 48 hr of incubation..... | 100 |
| 6.4 | Pretreatment with trolox for 72 hr of incubation..... | 100 |
| 7 | Effects of trolox on low K^+ -induced injuries in cultured cerebellar granule neurons (determined by LDH release assay) | |
| 7.1 | Cotreatment..... | 101 |
| 7.2 | Pretreatment with trolox for 24 hr of incubation..... | 101 |
| 7.3 | Pretreatment with trolox for 48 hr of incubation..... | 102 |
| 7.4 | Pretreatment with trolox for 72 hr of incubation..... | 102 |
| 8 | Effects of pretreatment with geldanamycin and trolox on glutathione level in low K^+ -induced injuries on cultured cerebellar granule neurons..... | 103 |
| 9 | Effects of pretreatment with geldanamycin and trolox on low K^+ -induced injuries in cultured cerebellar granule neurons (determined by TBARS assay)..... | 103 |

LIST OF FIGURES

| Figure | Page |
|---|------|
| 1 Chemical structure of geldanamycin..... | 6 |
| 2 Preparation of cerebellar granule neuronal cultures..... | 24 |
| 3 Structures of the yellow water soluble MTT and its dark blue insoluble formazan..... | 26 |
| 4 Principle of total glutathione quantification kit..... | 28 |
| 5 Effects of geldanamycin on mitochondrial activity in cultured cerebellar granule neurons..... | 35 |
| 6 Effects of geldanamycin on viability of cultured cerebellar granule neurons..... | 36 |
| 7 Time course of granule neuronal injuries induced by low K ⁺ medium..... | 37 |
| 8 Time course of granule neuronal cell death induced by low K ⁺ medium..... | 38 |
| 9 Effects of coexposure with geldanamycin on low-potassium-induced injuries in cultured cerebellar granule neurons..... | 39 |
| 10 Effects of coexposure with geldanamycin on low-potassium-induced cell death in cultured cerebellar granule neurons..... | 40 |
| 11 Effects of 6 hr pre-exposure with geldanamycin on low K ⁺ -induced injuries in cultured cerebellar granule neurons..... | 41 |
| 12 Effects of 12 hr pre-exposure with geldanamycin on low K ⁺ -induced injuries in cultured cerebellar granule neurons..... | 42 |
| 13 Effects of 24 hr pre-exposure with geldanamycin on low K ⁺ -induced injuries in cultured cerebellar granule neurons..... | 43 |
| 14 Effects of 48 hr pre-exposure with geldanamycin on low K ⁺ -induced injuries in cultured cerebellar granule neurons..... | 44 |
| 15 Effects of 72 hr pre-exposure with geldanamycin on low K ⁺ -induced injuries in cultured cerebellar granule neurons..... | 45 |
| 16 Effects of pre-exposure with 0.10 μM geldanamycin on low K ⁺ -induced injuries in cultured cerebellar granule neurons..... | 46 |

LIST OF FIGURES (CONTINUED)

| | | |
|----|---|----|
| 17 | Effects of 6 hr pre-exposure with geldanamycin on low K ⁺ -induced cell death in cultured cerebellar granule neurons..... | 47 |
| 18 | Effects of 12 hr pre-exposure with geldanamycin on low K ⁺ -induced cell death in cultured cerebellar granule neurons..... | 48 |
| 19 | Effects of 24 hr pre-exposure with geldanamycin on low K ⁺ -induced cell death in cultured cerebellar granule neurons..... | 49 |
| 20 | Effects of 48 hr pre-exposure with geldanamycin on low K ⁺ -induced cell death in cultured cerebellar granule neurons..... | 50 |
| 21 | Effects of 72 hr pre-exposure with geldanamycin on low K ⁺ -induced cell death in cultured cerebellar granule neurons..... | 51 |
| 22 | Effects of pre-exposure with 0.10 μM geldanamycin on low K ⁺ -induced cell death in cultured cerebellar granule neurons..... | 52 |
| 23 | Effects of coexposure with trolox on low-potassium-induced injuries in cultured cerebellar granule neurons..... | 53 |
| 24 | Effects of coexposure with trolox on low-potassium-induced cell death in cultured cerebellar granule neurons..... | 54 |
| 25 | Effects of 24 hr pre-exposure with trolox on low K ⁺ -induced injuries in cultured cerebellar granule neurons..... | 55 |
| 26 | Effects of 48 hr pre-exposure with trolox on low K ⁺ -induced injuries in cultured cerebellar granule neurons..... | 56 |
| 27 | Effects of 72 hr pre-exposure with trolox on low K ⁺ -induced injuries in cultured cerebellar granule neurons..... | 57 |
| 28 | Effects of 24 hr pre-exposure with trolox on low K ⁺ -induced cell death in cultured cerebellar granule neurons..... | 58 |
| 29 | Effects of 48 hr pre-exposure with trolox on low K ⁺ -induced cell death in cultured cerebellar granule neurons..... | 59 |
| 30 | Effects of 72 hr pre-exposure with trolox on low K ⁺ -induced cell death in cultured cerebellar granule neurons..... | 60 |
| 31 | Effects of pre-exposure with geldanamycin on low K ⁺ -induced glutathione diminution in cultured cerebellar granule neurons..... | 61 |
| 32 | Effects of pre-exposure with geldanamycin on low K ⁺ -induced lipid peroxidation in cultured cerebellar granule neurons..... | 62 |

LIST OF ABBREVIATIONS

| | |
|--------------------|---|
| β | = beta |
| $^{\circ}\text{C}$ | = degree celcius |
| μg | = microgram |
| μl | = microlitre |
| μM | = micromolar |
| AA | = arachidonic acid |
| AMPA | = α -amino-3-hydroxy-5-methyl-oxazole-4-propionic acid |
| BaCl_2 | = barium chloride |
| BDL | = bile duct ligation |
| BDNF | = brain-derived neurotrophic factor |
| Ca^{2+} | = calcium ion |
| CCl_4 | = carbon tetrachloride |
| CGNs | = cerebellar granule neurons |
| CNS | = central nervous system |
| CNTF | = ciliary neurotrophic factor |
| DMEM | = Dulbecco's Modified Eagle's Medium |
| DMSO | = dimethylsulfoxide |
| DNA | = deoxyribonucleic acid |
| DNase | = deoxyribonuclease |
| DPBS | = Dulbecco's phosphate buffered saline |
| DPPH | = 1,1-diphenyl-2-picrylhydrazyl |
| DTNB | = 5,5'-dithiobis (2-nitrobenzoic acid) |
| ER | = endoplasmic reticulum |
| et al. | = et alii (and other) |
| FBS | = fetal bovine serum |
| FGFs | = fibroblast growth factors |
| GA | = geldanamycin |
| GSH | = glutathione |
| GSSG | = glutathione disulfide |
| HIV | = human immunodeficiency virus |
| HSF | = heat shock factor |

| | |
|------------------|---|
| HSPs | = heat shock proteins |
| IC ₅₀ | = median inhibition concentration |
| IGFs | = insulin-like growth factors |
| K ⁺ | = potassium ion |
| KCl | = potassium chloride |
| kg | = kilogram |
| L | = litre |
| LDH | = lactate dehydrogenase |
| MDA | = malondialdehyde |
| mg | = milligram |
| mM | = millimolar |
| MTT | = 3-(4,5 – dimethylthiazol – 2- yl) – 2,5 – diphenyltetrazolium bromide |
| Na ⁺ | = sodium ion |
| NADP | = nicotinamide adenine dinucleotide phosphate |
| NADPH | = nicotinamide adenine dinucleotide phosphate (reduced form) |
| NGF | = nerve growth factor |
| nm | = nanometer |
| NMDA | = N-methyl-D-aspartate |
| nmol | = nanomole |
| NOS | = nitric oxide synthase |
| NT3, NT4 | = neurotrophins 3 and 4 |
| PBS | = phosphate buffered saline |
| RNA | = ribonucleic acid |
| ROS | = reactive oxygen speices |
| s-ALP | = serum levels of alkaline phosphatase |
| s-ALT | = serum levels of alanine aminotransferase |
| s-AST | = serum levels of aspartate aminotransferase |
| SEM | = standard error of mean |
| SOD | = superoxide dismutase |
| TBA | = thiobarbituric acid |
| TBARS | = thiobarbituric acid reactive substance |
| TLC | = thin layer chromatography |
| TNB | = 5-thio-2-nitrobenzoate |

CHAPTER I

INTRODUCTION

Central nervous system (CNS) is highly susceptible to damage by a variety of biological agents. This problem is enhanced by the fact that neurons and neuron-derived cells, with few exceptions, do not renew themselves so a gradual reduction in these essential elements throughout a lifetime is unavoidable. The insidious reduction in the number of neurons and their synaptic connections eventually compromises virtually all CNS functions. Because of this, a prudent approach would be to minimize neuronal loss and thus forestall the associated neurophysiological and neurobehavioral decrements that are seemingly inevitable in the aged. This would be of particular importance under the current circumstances where improvements in medical sciences have ensured progressively greater longevity in succeeding generations of humans thereby rapidly increasing the number of individuals reaching advanced age in many well developed countries of the world.

In addition to physiological aging, humans are unfortunately subjected to neurotoxicity during their lifetime. Neurotoxicity can be defined as the capacity of chemical, biological, or physical agents to cause adverse functional or structural changes in the nervous system. Chemical exposure may adversely affect the structure of the nervous system leading to a neuronopathy, an axonopathy, or may cause functional alterations that can be detected as neurobehavioral, neurochemical, or neurophysiological changes. These changes are major deficits frequently observed in patients with neurodegenerative diseases, e.g., Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, and spinal muscular atrophy.

The death of central neurons has been widely recognized as a normal feature of vertebrate development. Programmed cell death (PCD) has a key role in normal development and throughout the entire life of any multicellular organisms. During embryogenesis, neuronal cell death adjusts the number of neurons to the size of the target innervated. When neurons fail to receive adequate trophic support they die, thus sculpting the neuronal population to match the requirement of the target. Previous studies suggest that some forms of developmental PCD in the mammalian brain occur via apoptosis, a physiological mechanism by which a cell dies via transcriptional and

translational activation of an intrinsic cell death or suicide program (Raff et al., 1993). In addition to the role of PCD in the differentiation and organization of the nervous system during its development, PCD is likely involved in the pathogenesis of degenerative neurological disorders, such as Alzheimer's disease (Cotman and Anderson, 1995), Huntington's disease (Portera-Cailliau et al., 1995), amyotrophic lateral sclerosis (Rabizadeh et al., 1995), and spinal muscular atrophy (Roy et al., 1995), in which neuronal loss is a prominent feature.

Oxidative stress is considered to be an important causative factor in the onset or progression of neurodegenerative diseases and may contribute to neuronal damage resulting from cerebral ischemia (Coyle and Puttfarcken, 1993). Reactive oxygen species (ROS), which are generated as byproducts of many metabolic processes, including monoamine metabolism (Maher and Davis, 1996), the mitochondrial electron transport chain (Tan et al., 1998a) and arachidonic acid oxidation (Li et al., 1997b), may be the principal mediators of cell death in oxidatively stressed neuronal cells (Chan, 1996). The damage imparted on various macromolecules by chemical reactions with ROS can initiate an apoptotic program of cell death (Liu et al., 1996) or lead to cell death by necrosis (Choi, 1996).

In vitro models that recapitulate neuronal apoptosis are essential for studying the molecular mechanisms underlying cell death, and may prove useful for developing neuroprotective agents as well as therapeutic interventions for neurodegenerative disorders. One of the best in vitro models of neuronal apoptosis is represented by the change of culture conditions of cerebellar granule neurons (CGNs). This neuronal population, cultured in 25 mM KCl-containing medium, develops typical in vitro features of mature CGNs in vivo, such as an extensive neuritic network, expression of excitatory amino acid receptors, and production and release of L-glutamate (Burgoyne et al., 1993). When deprived of depolarizing levels (25 mM) of extracellular K^+ , CGNs undergo apoptosis (Gallo et al., 1987), showing typical cell shrinkage, chromatin condensation, pyknosis, and nucleosomal size DNA fragmentation (D'Mello et al., 1993, 1998; Galli et al 1995; Schulz et al., 1998). These are the conformational and physiological hallmarks of granule cell "programmed death" in which an alteration of reactive oxygen species (ROS) metabolism and cellular redox state has been implicated as mediator of CGN apoptotic death (Hockenbery et al.,

1993; Simonian and Coyle, 1996; Atlante et al., 1998). In this connection, the model of apoptotic neuronal death which consists of shifting K^+ concentration in the medium of cultured rat cerebellar granule cells from 25 to 5 mM has been widely used in neurotoxicological studies.

Geldanamycin (GA), a benzoquinone ansamycin antibiotic produced by *Streptomyces hygroscopicus* var. *geldanus*, is strongly cytotoxic against tumor cells, fungi and protozoa, as well as having weak anti-microbial activity (DeBoer et al., 1970). Recent study showed that very low concentrations of geldanamycin (0.5-2.0 nM) enhanced the survival and neurite outgrowth of cultured dorsal root ganglion (DRG) neurons (Sano, 2001). Cytostatic drugs, such as cisplatin, vincristine, and taxol are widely used in the treatment of various neoplasms. When these drugs are given in high doses to cancer patients, they cause irreversible toxic neuropathies in peripheral neurons. Therefore, there has been a great interest in therapeutic agents that can reduce these side effects. Consequently, these chemotherapeutic agents have been widely studied as toxic models of neuropathy. Addition of cytostatic drugs to the cultured embryonic DRG neurons decreased the outgrowth of neurites and induced apoptosis of the neurons. Geldanamycin was found to rescue cultured sensory neurons from apoptotic cell death by such antitumor drugs with sufficient trophic support by neurotrophins (Sano, 2001). This result suggests that geldanamycin has a therapeutic potential for neurodegenerative diseases, especially for anti-cancer drug-induced sensory neuropathy.

Previous study also showed that geldanamycin is effective in preventing glutamate-induced oxidative toxicity in the HT22 mouse hippocampal cell line, even if given 4 hr after glutamate treatment. Thus, geldanamycin may provide an effective strategy for manipulating signaling pathways in neuronal cells that use HSP90 as they proceed through a programmed cell death pathway in response to oxidative stress (Xiao et al., 1999).

From these interesting activities of geldanamycin, it is reasonable to investigate this natural product in term of its potential neuroprotective property in a well-characterized model of neurodegeneration. Therefore, the present study was carried out to determine effects of geldanamycin on low potassium-induced injuries in primary cultured rat cerebellar granule neurons. In this study, effects of geldanamycin

were compared with trolox, a potent antioxidant compound, by using biochemical analyses including MTT reduction assay, lactate dehydrogenase (LDH) release assay, thiobarbituric acid reactive substances (TBARS) assay and total glutathione assay.



สถาบันวิทยบริการ
จุฬาลงกรณ์มหาวิทยาลัย

CHAPTER II

LITERATURE REVIEW

Cerebellum

The cerebellum (Latin, little brain) is one of the most interesting structures in the central nervous system. First, by weight it constitutes only 10% of the total brain, yet it contains more than half of all neurons in the brain. Second, it has a highly regular structure. The cerebellar cortex has an almost crystalline organization suggests that all areas of the cerebellum perform a function on a different set of inputs. Third, the cerebellum is not necessary for basic perception or for the movement of muscle. Although both the sensory systems and the motor systems are mapped onto the cerebellum, complete destruction of the cerebellum produces no sensory impairment, and muscle strength typically remains intact. Rather, the cerebellum disrupts coordination of limb and eye movements, impairs balance, and decreases muscle tone. The signs of cerebellar damage thus differ dramatically from those of damage to the motor cortex (upper motor neuron disease, which reduces the strength and speed of movement and causes the patient to lose the ability to contract individual muscles. The cerebellum also regulates visceral output, but this function is less well understood.

Cerebellar granule neuron

Neurons are, by definition, postmitotic and therefore largely irreplaceable once they die. Neurons also communicate with each other at highly specialized structures called synapses, in which a neurotransmitter released from the presynaptic nerve endings. Synapses are often located at a relatively large distance away from the cell body, which is of considerable interest, since emerging data suggest synapses may be sites where neuronal apoptosis is often initiated (Mattson et al., 1998).

The cerebellar cortex of newborn rat, one of the best-studied regions of the developing brain, is a model well suited to identifying factors that control neuronal differentiation and apoptosis. In particular, cerebellar granule cells, which constitute the most abundant neuronal population in the mammalian CNS, have the advantages of a cell line without the drawbacks of transformed tumor cells. Granule cells have thus been widely used to investigate the neurotrophic or neurotoxic effects of various

factors and have provided crucial information regarding the basic molecular interplay of the cell death machinery (Vaudry et al., 2003).

Geldanamycin

Geldanamycin (GA), a naturally product, is produced by *Streptomyces hygroscopicus* var. *geldanus*.




Fig. 1 Chemical structure of geldanamycin

Physical appearance: Yellow solid

Molecular formula: C₂₉H₄₀N₂O₉

Molecular weight: 560.6

Purity: > 95%

Solubility: soluble in dimethyl sulfoxide (DMSO) (10mg/ml)

Storage: Store, as supplied, at -20 °C for up to 1 year. Store solution at -20 °C for up to 3 months.

Pharmacological and toxicological properties of GA

GA, a benzoquinone ansamycin class antibiotic, possesses selective tumoricidal activity in preclinical models and is initially developed to be an antitumor agent. GA has been used as a tyrosine kinase inhibitor and is known to inhibit signaling by steroid hormone receptors, Src and Raf (Pratt, 1998). Previous studies showed that GA exerted inhibitory effects on cancer cells and transformed cells (Sasaki et al., 1979) and also inhibited DNA synthesis (Yamaki et al., 1982). GA has

been reported to associate specifically with the ATP/ADP-binding domain of heat shock protein 90 (HSP90) (Stebbins et al., 1997), resulting in dissociation of complexes between HSP90 and its partners and accelerating the degradation of these proteins, including the glucocorticoid and dioxin receptors, Raf, erbB2 and mutated p53 (Chen et al., 1997; Schulte et al., 1997). In addition, GA blocked intracellular translocation of the glucocorticoid receptor, Raf and mutated p53 (Dasgupta and Momand, 1997). These results suggest that functioning of HSP90 in signal transduction in term of stabilization and translocation of its partners could be inhibited by GA.

Antitumor effect of GA

The antitumor effect of GA is thought to result from antagonizing HSP90 chaperone family - HSP90. Binding of GA to the ATPase pockets of the chaperone proteins HSP90 causes the degradation or down-regulation of their substances involving proliferation, cell cycle progression, gene expression and apoptosis. Simultaneous combinatorial impacts on multiple tumorigenic client proteins and pathways may account for the mechanism underlying the anticancer effect of GA.

The antitumor effects of GA likely result from the ability to deplete cells of two broad classes of growth-regulatory signaling proteins (Stebbins et al., 1997):

- 1). Proto-oncogenic protein kinases, including the erbB2 and EGF receptor tyrosine kinases, the v-Src family of non-receptor tyrosine kinases and the Raf-1, and CDK4 Ser/Thr kinases whose overexpression, or otherwise deregulation, has been observed in diverse human cancers; and

- 2). The nuclear hormone receptor family, including the estrogen and androgen hormone receptors which can drive the growth of hormone-dependent cancers of the breast and prostate, respectively.

Protective effect of GA against focal cerebral ischemia

Recent *in vivo* study showed that geldanamycin decreased infarct volume, decreased brain swelling, decreased the number of cells with DNA fragmentation, improved behavioral outcomes and protected brain against cerebral ischemia via induction of heat shock proteins (Lu et al., 2002).

Anti-inflammatory effect of GA

Histamine, vascular endothelial growth factor, acetylcholine, estrogen, as well as fluid shear stress activate a mechanism that recruits heat shock protein 90 (HSP90) to the endothelial nitric oxide synthase (eNOS). The interaction between HSP90 and eNOS enhances the activation of the enzyme in cells of intact blood vessels leading to nitric oxide (NO) production and is important for the function of eNOS in response to growth factors, G-protein activation, and mechanotransduction (Pritchard et al., 2001). Bucci et al. (2000) showed that geldanamycin inhibited endothelium-dependent relaxation of the rat aorta, mesentery, middle artery, and inhibited carrageenan-induced mouse paw edema in a dose-dependent manner. In conclusion, geldanamycin, an inhibitor of HSP90-dependent signal transduction, displays anti-inflammatory effect in vivo implying that HSP90 is critical for pathways involved in carrageenan-induced paw edema. In addition, Shastry and Joyner (2002) showed that GA could attenuate NO-mediated vasodilation in human skin. Thus, the ability of GA to block NO release and reduce edema formation suggests a therapeutic rationale for specific inhibitors of HSP90 as potential anti-inflammatory drugs.

Inhibition of Huntingtin protein aggregation in vitro

Huntington's disease (HD) is a progressive neurodegenerative disorder with no effective treatment. Sittler et al. (2001) showed that treatment of mammalian cells with GA at nanomolar concentrations induced the expression of HSP40, HSP70 and HSP90 and inhibited HD exon 1 protein aggregation in a dose dependent manner.

Mediation of superoxide formation

GA contains a quinone group and such quinone-containing molecules are well known to have redox-active properties. Quinone reacts with flavin-containing enzyme cytochrome P-450 reductases and ascorbate to form superoxide (O_2^-). Notably, the cytotoxicity of the ansamycin antibiotics has been attributed to radical generation. Superoxide production by GA could be particularly important in the interpretation of studies in which it is used to study the function of eNOS. If GA is releasing either O_2^- or promoting the release of this radical, physiological response to endogenously produced NO^\cdot may be lost because of the rapid reaction between NO^\cdot and O_2^- rather than by specific inhibition of HSP90 (Dikalov et al., 2002). Dikalov et al. (2002)

showed that GA markedly increased both endothelial and vascular smooth muscle cell production of O_2^- . These studies indicated that this effect of GA is dependent on nitric-oxide synthase but probably involves the interaction of this drug with both small molecule reductants and flavin-containing enzymes. Finally, the data suggest that O_2^- released from GA rapidly reacts with NO, reducing its ability to be trapped by Fe^{2+} (DETC).

Inhibition of platelet aggregation and disruption of membrane structure

Platelets are essential for hemostasis and normally circulate in a resting state. When exposed to agonists such as thrombin, ADP, and collagen, they can aggregate, change shape and secrete granule contents within seconds. Platelet activation by agonists leads to a change in the phosphorylation state of many platelet proteins on serine, threonine and/or tyrosine residues. In resting platelets, the state of protein phosphorylation must be actively balanced and ready to respond to agonist stimulation. In the study on human platelets, Suttitanamongkol et al. (2000) had found that GA inhibited platelet aggregation induced by ADP, thrombin and the thrombin-receptor-activating peptide. As a consequence, GA caused platelet plasma-membrane damage, detected by leakage of adenine nucleotides as well as serotonin. In conclusion, GA was able to disrupt membrane structure and inhibit platelet aggregation and caused major changes in protein phosphorylation in resting platelets as well as inhibiting increased phosphorylation in activated platelets.

Heat shock proteins (HSPs)

In all organisms proteins are continuously undergoing a folding process that is stabilized by a family of proteins known as chaperones. Molecular chaperones maintain the appropriate folding and conformation of proteins and are crucial in regulating the balance between protein synthesis and degradation. They have been shown not only to play a vital role in the cellular stress response but also to be important in regulating many important normal cellular functions, such as cell proliferation and apoptosis (Maloney and Workman, 2002).

Exposure of cells to a number of environmental stresses, including heat shock, alcohol, heavy metals, and oxidative stress results in the cellular accumulation of a number of chaperones, commonly known as heat shock proteins (HSPs). This effect is

mediated by the transcription factor heat shock factor 1 (HSF1) and is termed the 'heat shock response'. Induction of HSPs protects the cell against the initial stress insult, enhances recovery and leads to maintenance of a stress-tolerant state. It has become clear, however, that certain HSPs may also play a major molecular chaperone role under normal, stress-free conditions by regulating the correct folding, degradation, localization and function of a relatively small but growing list of important cellular proteins (Maloney and Workman, 2002).

A number of multigene families of HSPs exist, with individual gene products varying in cellular expression, function and localization. They are classified according to molecular weight e.g. HSP70, HSP90 and HSP27. Exceptions to this nomenclature rule are a small subset of chaperones that were identified as glucose regulated proteins e.g. GRP94 and GRP75.

Several diseases in humans can be acquired as a result of protein misfolding. Hence the development of therapies which modulate the molecular chaperone machinery may prove to be beneficial. In some conditions, e.g. Alzheimer's disease, prion diseases, and Huntington's disease, misfolded proteins can cause protein aggregation resulting in neurodegenerative disorders. Also, misfolded proteins may result in loss of wild-type protein function, leading to deregulated molecular and physiological functions in the cell. With specific reference to the recent review, HSPs have been implicated in cancer. For example, there is evidence of differential expression of HSPs which may relate to the stage of tumor progression. As a result of the involvement of HSP90 in various critical oncogenic pathways and the discovery that certain natural products with anticancer activity are targeting this molecular chaperone, the fascinating new concept has been developed that inhibiting HSP function may be useful in the treatment of cancer (Maloney and Workman, 2002).

Heat shock protein 90 (HSP90)

HSP90 is a highly abundant protein which is essential for cell viability and it exhibits dual chaperone functions. It plays a key role in the cellular stress response by interacting with many proteins after their native conformation has been altered by various environmental stresses, such as heat shock, ensuring adequate protein folding and preventing non-specific aggregation. In addition, recent results suggest that HSP90 may also play a role in buffering against the effects of mutation, presumably

by correcting the inappropriate folding of mutant proteins and is required for the activation of several families of eukaryotic protein kinases and nuclear hormone receptors, many of which are protooncogenic and play a prominent role in cancer. However, HSP90 also has an important regulatory role under normal physiological conditions and is responsible for the conformation stability and maturation of a number of specific client proteins. These can be subdivided into three groups: steroid hormone receptors, serine/threonine or tyrosine kinases, and a collection of apparently unrelated proteins, including mutant p53. All of these proteins play key regulatory roles in many physiological and biochemical processes in the cell (Maloney and Workman, 2002)

HSP90: the target of the anti-tumor drugs geldanamycin

Specific inhibitors identified in the screening for natural substances that inhibit proliferation of tumor cells are important new tools for analysis of HSP90 function *in vivo* and *in vitro*. One of these, geldanamycin (GA), initially seemed to decrease the activity of certain cell-cycle kinases. It was therefore thought to be a kinase inhibitor. Surprisingly, however, the only cellular protein to which GA binds is HSP90 (Whitesell et al., 1994). The effect of GA on kinase activity is thus indirect and due to inhibition of HSP90, which affects kinase folding.

GA binds to the N-terminal domain of HSP90 (Stebbins et al., 1997; Grenert et al., 1997). Initially, studies suggested that the GA-binding pocket is the peptide-interaction site (Stebbins et al., 1997). Later, however, it was shown that the GA-binding site and ATP-binding site are identical and that GA is a competitive inhibitor. GA mimics the unusual kinked conformation of ATP extremely well; the complex formed is orders of magnitude more stable than that formed by ATP and HSP90.

Analysis of the effects of GA on steroid-receptor activation indicated that GA interferes with the binding of the partner protein p23 (Johnson, J. and Toft, D.O., 1995) and therefore blocks the chaperone cycle at the intermediate complex (Smith et al., 1995). Whether addition of GA leads to the release of non-native proteins from HSP90 or to prolonged binding is controversial. *In vitro* evidence suggests that, in addition to GA exerting effects on the association between p23 and HSP90, the compound directly influences the binding of non-native proteins to HSP90 (Scheibel et al., 1998).

Stress response mechanisms are essential for the maintenance of cellular integrity and viability. Diverse stress conditions converge to enhance the synthesis of HSPs, many of which function as molecular chaperones in protein biosynthesis, folding, assembly, translocation, and degradation (Bukau, B., and Horwich, A.L., 1998). In addition to preventing proteotoxic damage, HSPs also appear to be involved in antiapoptotic pathways (Buzzard et al., 1998). In animal models as well as in vertebrate cell culture models, overexpression of specific HSPs decreases cytotoxicity induced by different environmental stress conditions, including thermal and oxidative challenges, ischemia, or exposure to toxic chemicals. In the nervous system, HSPs are thought to play an important role in a variety of pathophysiological states, including neurodegenerative diseases, cerebral ischemia, epilepsy, and trauma.

Apoptosis and the nervous system

The life history of all neurons consists of several neurogenerative stages, including induction, differentiation, proliferation, migration, and formation of axonal pathways and synaptic connections, that eventually confer a specific physiological function to each neuron. However, in many parts of the CNS and PNS, roughly half of the neurons undergo an additional stage in which regression leading ultimately to death occurs. This relatively large loss of the neurons is a common feature in many types of neurons (motor, sensory, interneurons, autonomic, etc.), occurs in all vertebrates, and appears to have evolved as an adaptive mechanism during development of the nervous system (Oppenheim, 1991). It is known now that such large-scale cell death occurs in oligodendrocytes also (Barres et al., 1992). The general explanation for this phenomenon is that the survival of developing vertebrate neurons depends on specific neurotrophic factors secreted by the target cells that the neurons innervate. There is excellent experimental proof for the above hypothesis and several neurotrophic factors called “neurotrophins”, like nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophins (NT)-3/4/5 have been shown to promote the survival of specific developing neurons. In addition, the developing neurons also require signals from other neurons that innervate them, some require specific hormones, and perhaps some require signal from neighboring glial cells as well (Raff et al., 1993). Thus, the survival of neurons depends on a complex interplay of several factors, and any imbalance in these inputs may lead to cell death. The beneficial effect of this mechanism is that although many types of neurons are

produced in excess, only a portion of them get sufficient neurotrophic support for their survival, and the rest die facilitating appropriate neuron-target cell innervation.

The cell death phenomenon, apart from being an important feature in the development of the nervous system, appears also to be a cause for many neurodegenerative diseases. Many neurological diseases are characterized by the gradual loss of specific sets of neurons and result in disorders of movement and CNS function. Such diseases are Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, several forms of cerebellar degeneration, spinal muscular atrophy, Alzheimer's disease and Huntington's disease. Aging, which may be considered as the terminal phase in the development of an organism, may also be a manifestation of specific neuronal loss by cell death. Several factors, such as oxidative stress, excitatory toxicity, inappropriate Ca^{2+} homeostasis, mitochondrial dysfunction, and lack of sufficient neurotrophic factors, have all been shown to contribute to the above-mentioned disorders. The available evidence indicates that the survival of neurons and their death are highly regulated, a dynamic events that depend on a number of internal and external factors, with vital consequences to the well-being of an organism.

Kerr et al. (1972) described two types of cell death. One, called "cell necrosis," results from injury and causes inflammation. The other, called "apoptosis," is the normal developmental type with several distinct characteristics. The term apoptosis is derived from Greek roots meaning "dropping of leaves off a tree." A number of features defines apoptosis and differentiates it from necrosis, although some features are also overlapping with necrosis. A principle distinguishing factor is that apoptotic cell death is an "active" process, for which protein synthesis is required. During this process, there is consecutive activation of a variety of otherwise dormant pathways. Thus, apoptosis may be conceived of as "programmed active cell death," as opposed to "passive cell death." This distinction has led to the denotation of apoptosis as "cell suicide." Another significant feature of apoptosis is that it usually involves isolated single cells, with topographically and temporally dispersed cell death within an organ. In contrary, necrosis often occurs in a regional group of cells at a particular point in time.

Pathological features of apoptosis include a number of attributes morphologically and biochemically distinguishing the process from necrosis. Most of

these are at the single cell level, although necrosis is usually a more massive phenomenon, affecting whole tissues, while apoptosis usually involves single cells, as mentioned above. Necrosis involves substantial cell swelling, with membrane breakdown and leakage of cell contents extracellularly. Apoptosis classically involves involutional change, with cell shrinkage being the characteristic shape change. During necrosis, the cytoplasmic organelles, such as mitochondria and lysosomes, usually swell and lyse, while in apoptosis there is contraction, with formation of “apoptotic” bodies, or small dense vesicular units that are phagocytized by macrophage without an inflammatory response. Apoptosis involves plasma membrane changes, clearly visualized in culture, but also recognizable in vivo, with marked cytoplasmic blebbing and involution. Nuclear changes of necrosis consist of disruption of nuclear membrane integrity; nuclear contents may show histopathological fading or intensifying, sometimes with fragmentation of the nucleus. By contrast, in apoptosis, the characteristic nuclear changes involve clumping of chromatin, sometimes leading to a “spoked wheel” appearance. A prominent molecule hallmark of apoptosis is a specific pattern of internucleosomal fragmentation of DNA. This leads to the appearance on agarose gel electrophoresis bands differing from their neighbors in molecular weight multiples of about 180 base pairs. In necrosis, there is also DNA breakdown, but it is apparently more diffuse and random, leading to a “smear” on gel electrophoresis rather discrete multiple bands (Lawrence et al., 2000). Biochemical changes that may distinguish apoptosis and necrosis in neurons are beginning to be identified. Neurons undergoing apoptosis exhibit: rapid increases in prostate apoptosis response-4 (Par-4) protein levels (Guo et al., 1998; Chan et al., 1999); translocation of one or more members of the Bcl-2 protein family to mitochondrial membranes (Putcha et al., 1999); mitochondrial membrane depolarization and release cytochrome C into the cytoplasm (Neame et al., 1998); activation of one or more members of the caspase family of cysteine proteases (Chan and Mattson, 1999); loss of plasma membrane phospholipid asymmetry which manifests in the presence of phosphatidylserine on the cell surface (a signal for engulfment by microglia); and nuclear DNA fragmentation (Kruman et al., 1997; Mattson et al., 1998). These changes are typically not observed in neurons undergoing necrosis.

Induction of apoptosis

A variety of compounds and experimental conditions have been found to induce apoptosis in cells of the nervous system, and these may be classified as shown in Table 1

Table 1. Inducers of apoptosis in cells of the nervous system

| Group | Conditions/agent | Cell type |
|------------------------------------|---|--|
| A | Neurotrophic factors | Sympathetic neurons |
| | Withdrawal of NGF from culture medium | Chick embryo sensory neurons |
| | | Motoneurons |
| | Withdrawal of serum from culture medium | Cortical neurons |
| | | Cerebellar granule cells |
| | | Proliferating cell line of neuronal origin |
| | Insulin deprivation | Cerebellar granule cells |
| | Glial-derived neurotrophic protein S100 β | Astrocyte-neuron cocultures |
| | Basic fibroblast growth factor | Chick embryonic neural retinal cells |
| B | Changing from a high K ⁺ (25 mM) to a low K ⁺ (5 mM) medium | Cerebellar granule cells |
| | | Cerebellar neurons |
| C | Addition of modulators of protein phosphorylation | Cortical neurons |
| | protein kinase inhibitor: staurosporine | Embryonic chick cerebral neurons |
| | | Cerebellar granule neurons |
| | | Embryonic astrocyte culture |
| | | Sympathetic neurons |
| | | Hippocampal neurons |
| D | DNA-damaging agents and nucleosides | |
| | Topoisomerase-1 inhibitor: camptothecin | Cortical neurons |
| | Topoisomerase-2 inhibitors:tenoposide and mitoxantrone | Sympathetic neurons |
| | | Sympathetic neurons |
| | Etoposide | Cultured neurons |
| | Arabinonucleosides of adenine, cytosine, guanine, and thymidine | Sympathetic neurons |
| | 2-Deoxyadenosine | Cerebellar granule cells |
| | 2-Chloroadenosine | Chick embryonic sympathetic neurons |
| N-Methyl-N'-nitro-N-nitrosoguanine | Cultured astroglial cells | |

| Group | Conditions/agent (cont.) | Cell type |
|-------|--|--|
| E | Effectors of calcium homeostatis Calcium ionophores Endoplasmic reticular Ca^{2+} -ATPase inhibitor :thapsigarin | Central neural cell line Cultured cortical neurons GT1-7 murine hypothalamic cell line |
| F | Neurotransmitters Excitatory amino acids Glutamate NMDA/quisqualate Dizocilpine (injected into animals) Kainic acid (injected into animals) Dopamin | Cultured neurons Freshly isolated cortical neurons Hippocampal neurons Cultured cortical neurons Cerebellar granule cells Developing brain Cultured neurons Cerebellar granule cells Hippocampal entorhinal sensory cortex Hippocampus inner cortical layers Primary striatal cultures Olfactory neuronal cell line |
| G | Peptides and proteins Amyloid β -peptide Recombinant HIV-1 gp120 Soluble macrophage proteins | Cultured cortical neurons Cultured hippocampal neurons Cortical neurons Cultured hippocampal neurons |
| H | Oxidative stress Ischemia (artery occlusion, reperfusion) Hypoxia High oxygen (50% oxygen atmosphere) Hydrogen peroxide Glutamate-induced glutathione depletion 3-Hydroxykynurenine Inhibition of SOD | Cerebral neurons Hippocampal neural cell line Neurons cocultured with astrocytes Cultured hippocampal neurons Neuroblastoma Cortical neurons Cultured striatal neurons Spinal cord organotypic cultures |
| I | NO NO donors: sodium nitroprusside and S-nitroso-N-acetylpenicillamine | Human neuroblastoma cell line |

| Group | Conditions/agent(cont.) | Cell type |
|-----------------------|---|---|
| J | NO-releasing compound Treatment with interferon- γ plus interleukin-1 β | Human neuroblastoma cell line Primary human neuronal/glial mixed culture |
| | Lipids Ceramide | Primary culture of mesencephalon Cerebellar granule cells |
| | Retinoic acid | Astrocyte culture Hippocampal neurons |
| | Lysophosphatidic acid Phosphatidylinositol 3-kinase inhibitors | Embryonic stem cell line Embryonic carcinoma cells |
| | Cholesterol | Cultured hippocampal neurons Cerebellar granule cells Cerebellar neurons |
| K | Irradiation | Cultured cerebellar neurons |
| | Ultraviolet χ irradiation γ irradiation | Cultured hippocampal neurons 3-day-old rat brain neurons Fetal rat brain |
| | Ionizing radiation | Cerebellar granule cells in vivo Cultured cerebellar neurons Cultured hippocampal neurons |
| L | Neurotoxicants | Cerebellar granule cells |
| | MPP ⁺ | Substantia nigra |
| | MDMA | Human serotonergic JAR cells |
| | Cocaine | Neuronal cultures |
| | Ethanol | Cerebellar granule cells |
| | Methyl mercury | Cerebellar neurons |
| | Dibutyryl cyclic AMP | Neuroblastoma B50 and B104 cells |
| | Cycloheximide | Neuroblastoma B50 and B104 cells |
| Dimeric interleukin-2 | Cultured oligodendrocytes | |
| Colchicine | Cerebellar granule cells | |

Low potassium-induced apoptosis

The mammalian nervous system is critically dependent on trophic support for proper development and survival (Barde, 1989). Among the molecules shown to influence neuronal differentiation and survival are the neurotrophins including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophins 3 and 4 (NT3 and NT4), the fibroblast growth factors (FGFs), ciliary neurotrophic factor (CNTF), insulin, and the insulin-like growth factors (IGFs) (Knusel et al., 1990).

In culture, neuronal survival can also be supported by various agents in the absence of any neurotrophic factors. One of these agents is K^+ . Depolarization by high levels of extracellular K^+ concentration ($[K^+]$) promotes survival of several types of neurons in vitro (Koike et al., 1989; Gallo et al., 1990; Franklin and Johnson, 1992). Besides supporting neuronal survival, high K^+ also influence neuronal development and phenotypic characteristics (Chalazonitis and Fishbach, 1980; Ishida and Deguchi, 1983; Resink et al., 1992). Although the ability of high $[K^+]$ to promote neuronal survival is well established, the mechanism by which it acts is not fully understood; $[K^+]$ may exert its rescuing activity through activation of dihydropyridine sensitive calcium channels (Gallo et al., 1987; Koike et al., 1989).

Among the various cell types known to be dependent on high K^+ for survival in vitro are cerebellar granule neurons (Lasher and Zagon, 1972; Levi et al., 1984; Gallo et al., 1990), which constitute the most abundant neuronal population in the mammalian brain. The natural neurotrophic factor, if it exists, that promotes survival of cerebellar granule neurons has not yet been identified. D'Mello et al. (1993) found that lowering the potassium concentration induced apoptosis in these neurons. The death process is dependent on the synthesis of both new RNA and proteins. Insulin-like growth factor I and cyclic AMP can protect the granule neurons from apoptosis in low K^+ . Wood et al. (1993) found the in vivo correlate of apoptosis in cerebellar granule cells - naturally occurring DNA fragmentation in the granular layer of newborn rat cerebellum. Dissociated cerebellar granule neurons from neonatal rats (postnatal day 8) differentiate acquiring morphological, biochemical, and electrophysiological characteristics of mature neurons (Lasher and Zagon, 1972; Hockberger et al., 1987; Cull-Candy et al., 1988; Gallo et al., 1990) and serve as an excellent model to study the molecular mechanism of PCD. In several studies on cerebellar granule cells

(D'Mello et al., 1993, 1998; Galli et al., 1995; Miller et al., 1996; Nath et al., 1996; Taylor et al., 1997) and cerebellar neurons (Kunimoto, 1994), changing $[K^+]$ from 25 mM to 5 mM in the culture medium resulted in neuronal apoptosis.

When cerebellar granule neurons obtained from postnatal rats are cultured in medium containing serum and depolarizing level of K^+ (25 mM), they can survive and mature *in vitro*. After culture and maturation in HK medium, lowering the K^+ concentration (5 mM) in the medium without serum induced death of cultured granule neurons. This LK-induced cell death occurs via apoptosis, as demonstrated by the typical hallmarks of apoptosis such as membrane blebbing, nuclear and cytoplasmic condensation, and DNA fragmentation (D'Mello et al., 1993; Galli et al., 1995; Schulz et al., 1996). An alteration of reactive oxygen species (ROS) metabolism and cellular redox state have also been implicated as mediators of CGC apoptotic death (Simonian and Coyle, 1996; Atlante et al., 1998). A sequential requirement for new mRNA formation, protein synthesis, caspase activation, and finally ROS overproduction during CGC apoptosis has been demonstrated (Schulz et al., 1996). Free radicals can act either as effectors of DNA, lipid, and protein damage or as signaling molecules via redox-sensitive cellular factors, such as nuclear factor- κ B (NF- κ B) (Bredesen, 1995). Other events during potassium deprivation-induced apoptosis include synthesis and phosphorylation of c-Jun (Watson et al., 1998), inactivation of phosphatidylinositol-3 (PI-3) and Akt kinase (D'Mello et al., 1997; Shimoke et al., 1997; Skaper et al., 1998) and BAD dephosphorylation (Gleichmann et al., 2000).

CHAPTER III

MATERIALS AND METHODS

Experimental Animals

Postnatal days 8, Wistar rat (both sexes) were used in this study. They were obtained from time-pregnant rats of embryonic day 18 that purchased from the National Laboratory Animal Center, Salaya, Mahidol University, Bangkok. All pregnant rats were housed in stainless steel cage until delivery and rat pups were kept with their mother until 8-day old. They were freely accessed food pellets (C.P. rat fed, Pokaphand Animal Fed Co. Ltd., Bangkok, Thailand) and water in the Central Animal House, Faculty of Pharmaceutical Sciences, Chulalongkorn University.

Chemicals

1. n-Butanol [BDH]
2. Butylated hydroxytoluene [sigma]
3. Calcium chloride [Ajax chemicals]
4. Cytosine arabinoside [Sigma]
5. Dimethyl Sulfoxide (DMSO) [BDH]
6. 5-5' dithiobis-(2-nitrobenzoic acid) (DTNB) [Sigma]
7. DNase I [Sigma]
8. Dulbecco's Modified Eagle's Medium (DMEM) [Sigma]
9. Dulbecco's Modified Eagle's Medium (DMEM) without phenol red [Sigma]
10. DMEM nutrient mixture F-12 HAM [Sigma]
11. Dulbecco's Phosphate-Buffered Saline (DPBS) [Sigma]
12. Equin Serum [Hyclone]
13. Ethanol [Merck]
14. Ether [Labscan]
15. Fetal Bovine Serum (FBS) [Hyclone]
16. Glutathione, reduced form [Sigma]
17. Glutathione reductase [Sigma]
18. Hank's Balance Salt Solution [Sigma]

19. HEPES [Sigma]
20. Hydrochloric acid [Merck]
21. Insulin [Sigma]
22. In vitro Toxicology Assay Kit (Lactate Dehydrogenase Based) [Sigma]
23. Magnesium chloride [Merck]
24. Magnesium sulphate heptahydrate [BDH]
25. Methanol [BDH]
26. MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) [Sigma]
27. β -Nicotinamide adenine dinucleotide phosphate, reduced form(β -NADPH) [Sigma]
28. Penicillin G [Sigma]
29. Phosphotungstic acid [Sigma]
30. Poly-D-Lysine Hydrobromide (MW 15,000-30,000) [Sigma]
31. Potassium chloride [Ajax chemicals]
32. Progesterone [Sigma]
33. Putrescine [Sigma]
34. Pyruvic acid sodium salt [Fluka]
35. Sodium selenite [Sigma]
36. Sodium bicarbonate [BDH]
37. Streptomycin sulfate [Sigma]
38. Sulfosalicylic acid [Sigma]
39. Sulfuric acid [BDH]
40. Thiobarbituric acid [BDH]
41. Transferrin [Sigma]
42. Trypsin [Sigma]
43. Triton X-100 [Sigma]
44. Trolox (a water-soluble vitamin E) [Sigma]
45. 0.04% Trypan blue [Sigma]

Application of Geldanamycin and Trolox

Geldanamycin (GA) was kindly provided by Dr. Khanit Suwanborirux (Department of Pharmacognosy, Chulalongkorn University).

Both geldanamycin and trolox solutions dissolved in DMSO were directly added to culture medium with a final concentration of DMSO less than 0.5% v/v.

Culture Media

All culture media were obtained from commercial sources in powder form. They were prepared by dissolving ingredients in nonpyrogenic distilled water followed by filtered sterilization through a 0.22 μm Millipore (Bedford, MA) filter. They were adjusted to pH 7.4 and kept at 4°C until used.

Dulbecco's Modified Eagle's Medium (DMEM, high glucose) was supplemented with 99 $\mu\text{g/ml}$ sodium pyruvate, 3.7 mg/ml sodium bicarbonate, 54 $\mu\text{g/ml}$ penicillin G sodium, 90 $\mu\text{g/ml}$ streptomycin sulfate and 10%(v/v) fetal bovine serum (FBS).

Serum-free DMEM was composed of normal DMEM without phenol red supplemented with 30 $\mu\text{g/ml}$ human transferrin, 5 $\mu\text{g/ml}$ insulin, 100 μM putrescin, 20 μM progesterone and 30 nM sodium selenite.

Instruments

1. Adjustable pipette: 10-100 μl [Nichiyō], 200-1000 μl , 1-5 ml [Labsystem]
2. Aluminium Foil [Tops]
3. Bunsen burner
4. Carbon dioxide incubator [Forma Scientific]
5. Cell culture dish : diameter 35 mm, diameter 100 mm [Nunc]
6. Cell strainer : 40 μm Nylon [Becton Dickinson]
7. Centrifuge [Kokusan]
8. Conical tube : 15 ml, 50 ml [Nunc]
9. Disposable glass pasteur pipettes : 230 mm [Volac]
10. Fluorescence spectrophotometer FS 777 [Jasco]
11. Glass bottle: 100 ml, 500 ml, 1000 ml [Schott Duran]
12. Hemocytometer (Depth 0.100 mm)[Improved Neubauer]
13. Inverted microscope, Axiovert 135 [Zeiss]
14. Laminar air flow hood [Hepaco]
15. Latex Free Syringe : 10 ml [Becton Dickinson]

16. Microliter pipette : 10-100 μ l [Nichiryo]
17. Microliter pipette : 200-1000 μ l, 1-5 ml [Labsystems]
18. Microplate reader [Anthos htl]
19. Needle-18 G
20. pH meter [Beckman Instrument]
21. Surgical equipments
22. Sterile Millex – GV (0.22 μ m filter unit) [Millipore]
23. Sterivex – GS (0.22 μ m filter unit with filling bell) [Millipore]
24. Sonicator [Elma]
25. Vortex mixer [Clay adams]
26. Water bath [Thelco]
27. 24-well cell culture plate [Nunc]
28. 96-well microtiter plate [Nunc]


Methods

Culturing of cerebellar granule neurons

Preparation of primary cultures of cerebellar granule neurons was carried out as described in details by Unchern et al (1997) using pooled cerebella of postnatal rats. Cerebella were removed from the brains of 8-day-old Wistar rats, a time when many of the granule neurons were still at an early post-mitotic stage of differentiation. After removal of the meninges the tissue was cut into pieces and incubated for 20 min at 37 $^{\circ}$ C with 0.25% trypsin and 0.01% DNase I in Ca^{2+} , Mg^{2+} -free Hank's balanced salt solution. The incubation was terminated by the addition of heat-inactivated horse serum and tissue fragments were centrifuged at 3,000 rpm for 10 min. The tissue pellet was gently rinsed and resuspended in high K^{+} (25 mM KCl) DMEM containing 10% FBS. The single cells were dissociated by gently passing the suspension through a 10-ml plastic pipette tip and then a flame-polished Pasteur pipette tip. The cell suspension was filtered through two sheets of nylon net (50 μ m-mesh) to remove cell lumps. The cells were counted on hemocytometer using trypan blue exclusion and diluted as appropriate with high K^{+} DMEM containing 10% FBS and plated on poly-D-lysine (100 μ g/ml) coated plates at a density of 1×10^6 cells/cm 2 in 24-well plates. The cultures were grown in a humidified 5% CO_2 - 95% air atmosphere at 37 $^{\circ}$ C. At 18-24 hr after plating, cytosine arabinoside was added to the medium to a final

concentration of 10 μM ; this curtails the number of astrocytes that develop in the cultures. One-third of volume of each well was replaced with fresh high K^+ (25 mM KCl) DMEM containing 10% FBS on day 4. Cultures were used on day 8 at which the medium was changed to serum-free low K^+ (5 mM KCl) DMEM or serum-free high K^+ (25 mM KCl) DMEM with/without phenol red plus desired concentrations of geldanamycin or trolox.

Fig. 2 Preparation of cerebellar granule neuronal cultures



Treatment of primary cerebellar granule neuronal cultures

Effects of geldanamycin on cultured rat cerebellar granule neurons

Cultures were exposed to geldanamycin at the concentrations of 0.01, 0.05, 0.1, 0.5, and 1.0 μM for 12, 24, 48, and 72 hours in serum-free high K^+ (25 mM KCl) DMEM containing N2 supplements. Cell viability was measured by MTT reduction assay and LDH release assay to determine the effects of time and concentration of exposure with geldanamycin.

Time course of low K^+ -induced injuries on cultured rat cerebellar granule neurons

Cultured neurons were switched from culture medium containing 10% fetal bovine serum and 25 mM KCl to serum-free DMEM containing 5 mM KCl. Cultures were exposed to serum-free low K^+ (5 mM KCl) DMEM containing N2 supplements for 6, 12, 18, 24, 36, and 48 hours. Cell viability was measured by MTT reduction assay and LDH release assay to determine the time course of low K^+ -induced injuries.

Effects of coexposure with geldanamycin or trolox on low potassium-induced injuries in cultured rat cerebellar granule neurons

Cultures were incubated with geldanamycin at the concentrations of 0.01, 0.025, 0.05, 0.075, and 0.1 μM or trolox at the concentrations of 10, 25, 50, 75, and 100 μM for 24 hours in serum-free low K^+ (5 mM KCl) DMEM containing N2 supplements. After the incubation period, MTT reduction assay and LDH release assay were done. In certain experimental conditions, TBARS assay and glutathione assay were also performed.

Effects of preexposure with geldanamycin or trolox on low potassium-induced injuries in cultured rat cerebellar granule neurons

Cultures were first incubated with geldanamycin at the concentrations of 0.01, 0.025, 0.05, 0.075, and 0.1 μM or trolox at the concentrations of 10, 25, 50, 75, and 100 μM for 6, 12, 24, 48, 72 hours in serum-free high K^+ (25 mM KCl) DMEM containing N2 supplements. After the incubation period, cultured cells were switched to fresh serum-free low K^+ (5 mM KCl) DMEM containing N2 supplements for 24 hr.

Then MTT reduction assay and LDH release assay were done. In certain experimental conditions, TBARS assay and glutathione assay were also performed.

Analysis of cell viability

MTT reduction assay

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay is a simple non-radioactive colorimetric assay to measure cell cytotoxicity, proliferation or viability. MTT is a yellow water-soluble tetrazolium salt. Metabolically active cells are able to convert the dye to a water-insoluble dark blue formazan by reductive cleavage of the tetrazolium ring by mitochondrial dehydrogenase of living cells. The resulting intracellular purple formazan can be measured by spectrophotometry after extraction by dimethyl sulfoxide. This assay is used to measure changes in cell proliferation rate and conversely, when metabolic events lead to apoptosis or necrosis, MTT reduction decreases, reflecting the loss of cell viability.




Fig. 3 Structure of the yellow water soluble MTT and its dark blue insoluble formazan

In this study, the MTT reduction assay technique was modified from Mossman, 1983 and Hansen et al., 1989. To determine the direct influence of screening substances on the MTT-tetrazolium reduction, these substances or extracts were incubated in free system and the formation of formazan was determined. 16 μ l of the MTT dye solution [5mg/ml in phosphate-buffered saline (PBS) pH 7.4, MTT Sigma] was added to cell culture medium in each well (final concentration were 100 μ g/ml). The assay was incubated in CO₂ incubator at 37°C for 1 hr and the medium in each well was aspirated off without disturbing the formazan precipitate.

Then 400 µl of DMSO was added to each well in order to solubilize the formazan crystals. Following through formazan solubilization, 200 µl aliquots of soluble formazan were transferred to a 96-well microtiter plate. The amount of MTT formazan product was determined by measuring absorbance with a microplate reader (Anthos htl) at a test wavelength of 570 nm and a reference wavelength of 655 nm. The results were expressed in term of the percentage of absorbance in control cultures.

Lactate dehydrogenase (LDH) release assay

Lactate dehydrogenase release assay is a simple colorimetric assay for the quantitation of cytotoxicity/cytolysis based on the measurement of LDH activity released from damaged cells. Lactate dehydrogenase (LDH) leakage through the cell membrane is routinely used as an indicator of damage to plasma membrane integrity. An increase in LDH leakage into the extracellular environment indicates a loss of membrane integrity, and is interpreted as a cytotoxic effect.

Cell viability was determined by assaying the medium from each well for lactate dehydrogenase (LDH) activity using an in vitro toxicology assay kit (Takara, Japan) according to the manufacture's instructions. Briefly, medium LDH was assayed by pipetting 100 µl of culture medium from each well into a 96-well microtiter plate. Cellular LDH was measured by carefully aspirated off the remaining culture medium and solubilized cells with 1 ml of 0.5% Triton X-100 in PBS after which 100 µl aliquots were pipette into a 96-well microtiter plate. The reaction was started by addition of 50 µl of lactate dehydrogenase assay mixture into each well. The reaction mixtures were protected from light and left at room temperature for 30 min. The reaction was terminated by adding 50 µl of 0.5 N HCl into each well. The light absorbance in each well was measured at 490-655 nm with a Biorad 3550 dual wavelength microplate reader. The LDH release which reflects cell death was presented as percentage of total LDH activity by the following formula:

$$\%LDH \text{ release} = \frac{LDH \text{ activity in medium} \times 100}{LDH \text{ activity in medium} + LDH \text{ activity in cells}}$$

In most cases, comparative LDH release in test conditions was expressed as the percentage of that in control conditions.

Glutathione assay

Glutathione (GSH) is the most abundant thiol (SH) compound in animal tissue, plant tissues, bacteria and yeast. GSH plays many different roles such as protection against reactive oxygen species and maintenance of protein SH groups. During these reactions, GSH is converted into glutathione disulfide (GSSG: oxidized form of GSH). GSH measurement can be done in plasma, tissue samples and cultured cell.

DTNB (5,5'-Dithiobis(2-nitrobenzoic acid)), known as Ellman's Reagent, was developed for the detection of thiol compounds. In 1985, Dr. Anderson suggested that the glutathione recycling system by DTNB and glutathione reductase created a highly sensitive glutathione detection method. DTNB and glutathione (GSH) react to generate 2-nitro-5-thiobenzoic acid and glutathione disulfide (GSSG). Since 2-nitro-5-thiobenzoic acid is a yellow colored product, GSH concentration in a sample solution can be determined by the measurement at 450 nm absorbance (Tietze, 1969; Baker et al., 1990). GSH is generated from GSSG by glutathione reductase, and reacts with DTNB again to produce 2-nitro-5-thiobenzoic acid. Therefore, this recycling reaction improves the sensitivity of total glutathione detection (Fig. 5).




Fig. 4 Principle of total glutathione quantification kit

In this study, cells were washed twice in cold PBS, dissolved in 150 μ l of 1% w/v sulfosalicylic acid and left on ice for 10 min. Then, two wells of samples were pooled, transferred to Eppendorf tubes and centrifuged at 13,000 \times g for 5 min at 4°C. The supernatant was analyzed for total glutathione. A 20 μ l aliquot of supernatant was added into the well of a 96-well microtiter plate and adjusted to 100 μ l with 0.1 M phosphate buffer containing 1mM EDTA (pH 7.5). The reaction was initiated by addition of 100 μ l of reaction mixture [25 μ l of 0.15 mM 5,5'-dithiobis (2-

nitrobenzoic acid), 25 μ l of 0.2 mM NADPH and 50 μ l of 1 U GSH reductase in 0.1 M sodiumphosphate buffer (pH 7.5)]. The formation of 2-nitro-5-benzoic was monitored at 30-s intervals for 10 min at 450/620 nm by using a microplate reader [Anthos htl]. The slope of the initial rate of reaction was used for calculating GSH content from a standard curve obtained by plotting known amount of GSH (25-150 μ M). The cellular content of GSSG was typically less than 2 % of the GSH level and was not considered.

Thiobarbituric acid reactive substances (TBARS) assay

The sensitivity of measuring thiobarbituric acid reactive substances (TBARS) has made this assay the method of choice for screening and monitoring lipid peroxidation, a major indicator of oxidative stress (Yagi et al.,1998). Malondialdehyde (MDA), an end product of polyunsaturated fatty acid oxygenation, is a reliable and commonly used biomarker for assessing lipid peroxidation. MDA forms a 1:2 adduct with thiobarbituric acid (TBA) and produces a colored MDA-TBA adduct which can be measured by fluorometry or spectrophotometry.

TBARS was measured using a technique modified from Ohkawa et al. (1979) and Storch et al. (2000). Briefly, cultured cells were washed three times with Hank's balanced salt solution (HBSS) and lysed with 160 μ l of 2% sodium dodecyl sulfate for 30 min. Cell lysates from six cell culture wells were pooled, transferred to glass tube and adjusted with 2% sodium dodecyl sulfate to 1 ml. The lysates were added serially with 50 μ l of butylated hydroxytoluene (4% in ethanol), 1 ml of phosphotungstic acid (10% in 0.5 M sulfuric acid) and 1.5 ml of thiobarbituric acid (0.7%). The mixtures were incubated at 95^o C for 60 min, cooled by tap water, extracted with 4 ml of n-butanol and centrifuged at 3,500 rpm for 10 min. After centrifugation, the fluorescence of the n-butanol layer was measured at 515 nm excitation and 553 nm emission with Jasco FS 777 spectrofluorometer. Results are expressed in term of percentage control.

Statistical analysis

Data are expressed as mean \pm standard error of mean (SEM) from groups of 6-8 samples. Differences among experimental groups were assessed by one-way

analysis of variance (ANOVA) followed by Scheff's test for multiple comparisons. Statistical significance was considered with $P < 0.05$.



สถาบันวิทยบริการ
จุฬาลงกรณ์มหาวิทยาลัย

CHAPTER IV

RESULTS

1. Effects of geldanamycin on cell survival of cultured cerebellar granule neurons

After the exposure of cerebellar granule neurons to geldanamycin (GA) at different concentrations (0.01-1.0 μM) for various time intervals (12-72 hr), it appeared that low concentrations of GA (0.01-0.1 μM) produced no significant changes in cell metabolic activity. At concentrations higher than 0.50 μM with 12, 24, 48, and 72 hr of incubation, GA markedly decreased mitochondrial metabolic activity (Fig. 5). In addition, low concentrations of GA (0.01-0.1 μM) produced no significant neuronal cell death within the first 24 hr of exposure. However, after 24 hr of exposure, neuronal injuries and death were apparent with concentrations of GA higher than 0.50 μM . It was notable that with long-term exposure (after 72 hr of incubation), signs of neuronal cell death were also apparent with GA concentration of 0.05 μM (Fig. 6). Therefore, it was evident that GA might be cytotoxic to cultured cerebellar granule neurons if the concentrations or time of exposure were increased up to a certain limit.

2. Time course of low K^+ -induced injuries in cultured cerebellar granule neurons

To investigate the effect of low K^+ , cultured neurons were allowed to develop for 8 days in serum-containing medium and 25 mM K^+ (high K^+). The mature neurons were then shifted to serum-free medium containing 5 mM K^+ (low K^+). Control cells were maintained in serum-free medium with 25 mM K^+ . Cell death was not detectable within 6 hr of K^+ deprivation but < 50% of the cells were viable at 24 hr. Significant decrease of MTT reduction was observed as early as 12 hr of incubation and continued to decrease to the level of < 40% by 48 hr (Fig. 7). In addition, LDH release into the culture medium was low within 12 hr of K^+ deprivation but increased to \approx 50% by 24 hr and thereafter increased up to 48 hr of incubation (Fig. 8). Taken together, the results of these two assays indicated that neuronal death began after \sim 12 hr of K^+ withdrawal and proceeded rapidly within the next 12 hr and after 24 hr of K^+ deprivation, \sim 50% of the neurons had lost their viability. Therefore, as considered

from the time course of low K^+ -induced injuries in cultured cerebellar granule neurons, 24 hr of incubation with low K^+ was used as an insulting condition in subsequent experiments of this study.

3. Effects of cotreatment with geldanamycin on low K^+ -induced injuries in cultured cerebellar granule neurons

After the co-exposure of cultured cerebellar granule neurons with GA, at different concentrations (0.01-0.10 μ M), and low K^+ medium for 24 hr, GA aggravated the suppression of cell metabolic activity (to ~ 40-45% of control, $p < 0.05$) (Fig. 9). In addition, GA had no protective effect on neuronal death induced by low K^+ but instead significantly increased neuronal cell death (Fig. 10). A similar inability to prevent low K^+ -induced neuronal death was also seen with trolox. The co-incubation with 100 μ M trolox was not effective in preventing neurons from low K^+ -induced injuries.

4. Effects of pretreatment with geldanamycin on low potassium-induced injuries in cultured cerebellar granule neurons

After the pre-exposure of cultured cerebellar granule neurons with GA at different concentrations ranging from 0.01-0.10 μ M for 6, 12, 24, 48, and 72 hr of incubation, neurons were shifted to serum-free low K^+ medium (5 mM KCl) for 24 hr. Control cells were maintained in serum-free medium with high K^+ (25 mM KCl). It appeared that after 6 hr pre-exposure to 0.01-0.10 μ M of GA, the MTT reduction increased gradually up to 72 hr of incubation. At low concentrations of GA (0.01-0.025 μ M) with short incubation periods (6-12 hr), GA showed a little effect on neuronal metabolic activity. However, after 24-72 hr pre-exposure to GA at concentrations higher than 0.05 μ M, GA had a marked effect on neuronal metabolic activity as compared to neurons in serum-free medium containing 5 mM K^+ ($p < 0.05$) (Fig. 11-15). In addition, pre-exposure of cerebellar granule neurons to low concentrations of GA (0.01-0.025 μ M) for 6-12 hr had a little but statistically significant effect on neuronal survival as compared to neurons in serum-free medium containing 5 mM K^+ (Fig. 17-18). With 24 hr pre-exposure to GA at concentrations higher than 0.025 μ M, cell death caused by low K^+ was significantly prevented (Fig. 19-20). However, 72 hr incubation with 0.01-0.10 μ M GA failed to significantly

inhibit death of granule neurons that caused by K^+ deprivation (Fig. 21). Taken together, these biochemical assays indicate that GA exerts a concentration-dependent protective effect on low K^+ -induced injuries to cultured cerebellar granule neurons. Apparently, the maximal magnitude of protection may be obtained from 24 hr pre-exposure to 0.10 μ M GA (Fig.16, 22).

5. Effects of cotreatment with trolox on low potassium-induced injuries in cultured cerebellar granule neurons

After the co-exposure of cultured cerebellar granule neurons with trolox at different concentrations (10-100 μ M) and serum-free low K^+ medium (5 mM KCl) for 24 hr, it was apparent that trolox aggravated the suppression of cell metabolic activity (to > 50% of control, $p < 0.05$) (Fig. 23) and significantly increased neuronal cell death (Fig. 24).

6. Effects of pretreatment with trolox on low potassium-induced injuries in cultured cerebellar granule neurons

After the pre-exposure of cultured cerebellar granule neurons with trolox at different concentration ranging from 10-100 μ M for 24, 48, 72 hr and then switching to serum-free low K^+ medium (5 mM KCl) for 24 hr, trolox significantly increased mitochondrial metabolic damage and neuronal cell death (Fig. 25-30). These results, in conjunction with the results of cotreatment with trolox on low potassium-induced injuries in cultured cerebellar granule neurons, suggest that trolox, an effective antioxidant, had no protection effect on low K^+ induced-injuries under our experimental conditions.

7. Effects of pretreatment with geldanamycin on glutathione levels in cultured cerebellar granule neurons exposed to low potassium-medium

The exposure of cerebellar granule neurons for 24 hr in serum-free low K^+ medium caused a marked reduction of cellular GSH content to ~ 60% of control while the 24 hr exposure to 0.10 μ M GA or 100 μ M trolox alone significantly increased cellular GSH content to > 120% of control. However, incubation of cerebellar granule neurons for 24 hr in serum-free low K^+ medium after the pre-exposure to 100 μ M trolox for 24 hr did not prevent a decrease in cellular GSH content. Interestingly, pre-exposure to 0.10 μ M GA for 24 hr not only prevented low K^+ -induced diminution in

cellular GSH content but still boosted the GSH level up to 140% of control (Fig. 31). Therefore, these results suggest that GA possesses a remarked protective effect against K^+ deprivation-induced GSH depletion in cultured cerebellar granule neurons.

8. Effects of pretreatment with geldanamycin on lipid peroxidation in cultured cerebellar granule neurons exposed to low potassium-medium

Switching cultured cerebellar granule neurons from medium containing a high concentration of K^+ (25 mM KCl) to medium containing a low concentration of K^+ (5 mM KCl) for 24 hr significantly increased cellular lipid peroxidation. In contrast, exposure of cultured neurons with 0.10 μ M GA or 100 μ M trolox alone for 24 hr induced a marked decrease in cellular lipid peroxidation. Pre-exposure to 100 μ M trolox or 0.10 μ M GA for 24 hr in 25 mM K^+ before switching to 5 mM K^+ for 24 hr significantly prevented an increase in cellular lipid peroxidation (Fig. 32). Therefore, these results suggest that trolox and GA display a protective effect against K^+ deprivation-induced lipid peroxidation in cultured cerebellar granule neurons.




Fig. 5 Effects of geldanamycin on mitochondrial activity in cultured cerebellar granule neurons.

Cerebellar granule neurons were cultured for 8 days and then incubated with various concentrations of GA (0.01-1.0 μM). Neuronal injury was determined after 12, 24, 48, and 72 hr of incubation by examination of mitochondrial dehydrogenase activity (MTT reduction). Results are expressed as percentage of values from 25 mM K^+ -untreated control cells. Data are presented as mean \pm S.E.M of eight samples from duplicate experiments.

* $p < 0.05$ compared with untreated control (one way ANOVA and Scheff's test)




Fig. 6 Effects of geldanamycin on viability of cultured cerebellar granule neurons.

Cerebellar granule neurons were cultured for 8 days and then incubated with various concentrations of GA (0.01-1.0 μM). Neuronal cell death was determined after 12, 24, 48, and 72 hr of incubation by quantifying the released LDH activity. Results are expressed as percentage of values from 25 mM K^+ -untreated control cells. Data are presented as mean \pm S.E.M of eight samples from duplicate experiments.

* $p < 0.05$ compared with untreated control (one way ANOVA and Scheff's test)

สถาบันวิทยบริการ
จุฬาลงกรณ์มหาวิทยาลัย




Fig. 7 Time course of granule neuronal injuries induced by low K^+ medium

Cerebellar granule neurons were cultured in medium with 10% fetal bovine serum and 25 mM KCl for 8 days. The medium was replaced with a serum-free DMEM containing 5 mM KCl for 6, 12, 18, 24, 36, and 48 hr before determination of MTT reduction activity. Control cells were switched to a serum-free DMEM containing 25 mM KCl. Results represent the mean \pm S.E.M values of twelve samples taken from duplicate experiments.




Fig. 8 Time course of granule neuronal cell death induced by low K^+ medium

Eight days after plating, neurons were switched to serum-free DMEM containing low K^+ (5 mM). LDH activity in the culture medium was measured at 6, 12, 18, 24, 36, and 48 hr of incubation. Results represent the mean \pm S.E.M values of twelve samples taken from duplicate experiments and are expressed as percentage of total LDH activity in control cultures. In control cultures, neurons were maintained in serum-free with high K^+ (25 mM KCl).




Fig. 9 Effects of coexposure with geldanamycin on low-potassium-induced injuries in cultured cerebellar granule neurons

Cultured cerebellar granule neurons were exposed to various concentrations of GA (0.01-0.10 μ M) in serum-free DMEM containing low K⁺ (5 mM KCl) for 24 after which neuronal injury was determined by cellular MTT reduction activity. Results are expressed as percentage of values from 25 mM K⁺-untreated control cells. Data are presented as mean \pm S.E.M of eight samples from duplicate experiments.

*p < 0.05 vs untreated control cells (one way ANOVA and Scheff's test).




Fig. 10 Effects of coexposure with geldanamycin on low-potassium-induced cell death in cultured cerebellar granule neurons

Cultured cerebellar granule neurons were exposed to various concentrations of GA (0.01-0.10 μM) in serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr after which neuronal cell death was determined by quantifying the released LDH. Results are expressed as a percentage of values from 25 mM K⁺-untreated control cells.

* $p < 0.05$ vs untreated control, # $p < 0.05$ vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 11 Effects of 6 hr pre-exposure with geldanamycin on low-potassium-induced injuries in cultured cerebellar granule neurons

Cultured cerebellar granule neurons were exposed to various concentrations of GA (0.01-0.10 μM) in serum-free DMEM containing high K⁺ (25 mM KCl) for 6 hr and then switched to serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr. Cell injury was determined by mitochondrial metabolic activity (MTT reduction). Results are expressed as percentage of values from 25 mM K⁺-untreated control cells. Data are presented as mean \pm S.E.M of eight samples from duplicate experiments.

* $p < 0.05$ vs untreated control cells, # $p < 0.05$ vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 12 Effects of 12 hr pre-exposure with geldanamycin on low-potassium-induced injuries in cultured cerebellar granule neurons

Cultured cerebellar granule neurons were exposed to various concentrations of GA (0.01-0.10 μ M) in serum-free DMEM containing high K⁺ (25 mM KCl) for 12 hr and then switched to serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr. Cell injury was determined by mitochondrial metabolic activity (MTT reduction). Results are expressed as percentage of values from 25 mM K⁺-untreated control cells. Data are presented as mean \pm S.E.M of eight samples from duplicate experiments.

*p < 0.05 vs untreated control cells, #p < 0.05 vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 13 Effects of 24 hr pre-exposure with geldanamycin on low-potassium-induced injuries in cultured cerebellar granule neurons

Cultured cerebellar granule neurons were exposed to various concentrations of GA (0.01-0.10 μM) in serum-free DMEM containing high K⁺ (25 mM KCl) for 24 hr and then switched to serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr. Cell injury was determined by mitochondrial metabolic activity (MTT reduction). Results are expressed as percentage of values from 25 mM K⁺-untreated control cells. Data are presented as mean \pm S.E.M of eight samples from duplicate experiments.

*p < 0.05 vs untreated control cells, #p < 0.05 vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 14 Effects of 48 hr pre-exposure with geldanamycin on low-potassium-induced injuries in cultured cerebellar granule neurons

Cultured cerebellar granule neurons were exposed to various concentrations of GA (0.01-0.10 μM) in serum-free DMEM containing high K⁺ (25 mM KCl) for 48 hr and then switched to serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr. Cell injury was determined by mitochondrial metabolic activity (MTT reduction). Results are expressed as percentage of values from 25 mM K⁺-untreated control cells. Data are presented as mean \pm S.E.M of eight samples from duplicate experiments.

*p < 0.05 vs untreated control cells, #p < 0.05 vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 15 Effects of 72 hr pre-exposure with geldanamycin on low-potassium-induced injuries in cultured cerebellar granule neurons

Cultured cerebellar granule neurons were exposed to various concentrations of GA (0.01-0.10 μM) in serum-free DMEM containing high K⁺ (25 mM KCl) for 72 hr and then switched to serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr. Cell injury was determined by mitochondrial metabolic activity (MTT reduction). Results are expressed as percentage of values from 25 mM K⁺-untreated control cells. Data are presented as mean \pm S.E.M of eight samples from duplicate experiments.

* $p < 0.05$ vs untreated control cells, # $p < 0.05$ vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 16 Effects of pre-exposure with 0.10 μM geldanamycin on low-potassium-induced injuries in cultured cerebellar granule neurons

Cultured cerebellar granule neurons were exposed to various concentrations of 0.10 μM GA in serum-free DMEM containing high K^+ (25 mM KCl) for 0, 6, 12, 24, 48, and 72 hr and then switched to serum-free DMEM containing low K^+ (5 mM KCl) for 24 hr. Cell injury was determined by mitochondrial metabolic activity (MTT reduction). Results are expressed as percentage of values from 25 mM K^+ -untreated control cells. Data are presented as mean \pm S.E.M of eight samples from duplicate experiments.




Fig. 17 Effects of 6 hr pre-exposure with geldanamycin on low-potassium-induced cell death in cultured cerebellar granule neurons.

Cultured cerebellar granule neurons were exposed to various concentrations of GA (0.01-0.10 μM) in serum-free DMEM containing high K⁺ (25 mM KCl) for 6 hr and then switched to serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr. Neuronal cell death was determined by quantifying the released LDH. Results are expressed as a percentage of values from 25 mM K⁺-untreated control cells. Data represent mean \pm S.E.M values of eight samples from duplicate experiments.

*p < 0.05 vs untreated control cells, #p < 0.05 vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 18 Effects of 12 hr pre-exposure with geldanamycin on low-potassium-induced cell death in cultured cerebellar granule neurons.

Cultured cerebellar granule neurons were exposed to various concentrations of GA (0.01-0.10 μ M) in serum-free DMEM containing high K⁺ (25 mM KCl) for 12 hr and then switched to serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr. Neuronal cell death was determined by quantifying the released LDH. Results are expressed as a percentage of values from 25 mM K⁺-untreated control cells. Data represent mean \pm S.E.M values of eight samples from duplicate experiments.

*p < 0.05 vs untreated control cells, #p < 0.05 vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 19 Effects of 24 hr pre-exposure with geldanamycin on low-potassium-induced cell death in cultured cerebellar granule neurons.

Cultured cerebellar granule neurons were exposed to various concentrations of GA (0.01-0.10 μM) in serum-free DMEM containing high K⁺ (25 mM KCl) for 24 hr and then switched to serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr. Neuronal cell death was determined by quantifying the released LDH. Results are expressed as a percentage of values from 25 mM K⁺-untreated control cells. Data represent mean \pm S.E.M values of eight samples from duplicate experiments.

* $p < 0.05$ vs untreated control cells, # $p < 0.05$ vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 20 Effects of 48 hr pre-exposure with geldanamycin on low-potassium-induced cell death in cultured cerebellar granule neurons.

Cultured cerebellar granule neurons were exposed to various concentrations of GA (0.01-0.10 μM) in serum-free DMEM containing high K⁺ (25 mM KCl) for 48 hr and then switched to serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr. Neuronal cell death was determined by quantifying the released LDH. Results are expressed as a percentage of values from 25 mM K⁺-untreated control cells. Data represent mean \pm S.E.M values of eight samples from duplicate experiments.

* $p < 0.05$ vs untreated control cells, # $p < 0.05$ vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 21 Effects of 72 hr pre-exposure with geldanamycin on low-potassium-induced cell death in cultured cerebellar granule neurons.

Cultured cerebellar granule neurons were exposed to various concentrations of GA (0.01-0.10 μM) in serum-free DMEM containing high K⁺ (25 mM KCl) for 72 hr and then switched to serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr. Neuronal cell death was determined by quantifying the released LDH. Results are expressed as a percentage of values from 25 mM K⁺-untreated control cells. Data represent mean \pm S.E.M values of eight samples from duplicate experiments.

*p < 0.05 vs untreated control cells, #p < 0.05 vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 22 Effects of pre-exposure with 0.10 μM geldanamycin on low-potassium-induced cell death in cultured cerebellar granule neurons

Cultured cerebellar granule neurons were exposed to various concentrations of 0.10 μM GA in serum-free DMEM containing high K^+ (25 mM KCl) for 0, 6, 12, 24, 48, and 72 hr and then switched to serum-free DMEM containing low K^+ (5 mM KCl) for 24 hr. Neuronal cell death was determined by quantifying the released LDH. Results are expressed as a percentage of values from 25 mM K^+ -untreated control cells. Data represent mean \pm S.E.M values of eight samples from duplicate experiments.

จุฬาลงกรณ์มหาวิทยาลัย




Fig. 23 Effects of coexposure with trolox on low-potassium-induced injuries in cultured cerebellar granule neurons

Cultured cerebellar granule neurons were exposed to various concentrations of trolox (10-100 μM) in serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr. Cell injury was determined by mitochondrial metabolic activity (MTT reduction). Results are expressed as percentage of values from 25 mM K⁺-untreated control cells. Data are presented as mean \pm S.E.M of eight samples from duplicate experiments.

*p < 0.05 vs untreated control cells, #p < 0.05 vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 24 Effects of coexposure with trolox on low-potassium-induced injuries in cerebellar granule neurons.

Cultured cerebellar granule neurons were exposed to various concentrations of trolox (10-100 μM) in serum-free DMEM containing low K^+ (5 mM KCl) for 24 hr. Neuronal cell death was determined by quantifying the released LDH. Results are expressed as a percentage of values from 25 mM K^+ -untreated control cells. Data represent mean \pm S.E.M values of eight samples from duplicate experiments.

* $p < 0.05$ vs untreated control cells, # $p < 0.05$ vs low K^+ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 25 Effects of 24 hr pre-exposure with trolox on low-potassium-induced injuries in cultured cerebellar granule neurons

Cultured cerebellar granule neurons were exposed to various concentrations of trolox (10-100 μ M) in serum-free DMEM containing high K⁺ (25 mM KCl) for 24 hr and then switched to serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr. Cell injury was determined by mitochondrial metabolic activity (MTT reduction). Results are expressed as percentage of values from 25 mM K⁺-untreated control cells. Data are presented as mean \pm S.E.M of eight samples from duplicate experiments.

* $p < 0.05$ vs untreated control cells, # $p < 0.05$ vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 26 Effects of 48 hr pre-exposure with trolox on low-potassium-induced injuries in cultured cerebellar granule neurons

Cultured cerebellar granule neurons were exposed to various concentrations of trolox (10-100 μ M) in serum-free DMEM containing high K⁺ (25 mM KCl) for 48 hr and then switched to serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr. Cell injury was determined by mitochondrial metabolic activity (MTT reduction). Results are expressed as percentage of values from 25 mM K⁺-untreated control cells. Data are presented as mean \pm S.E.M of eight samples from duplicate experiments.

*p < 0.05 vs untreated control cells, #p < 0.05 vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 27 Effects of 72 hr pre-exposure with trolox on low-potassium-induced injuries in cultured cerebellar granule neurons

Cultured cerebellar granule neurons were exposed to various concentrations of trolox (10-100 μ M) in serum-free DMEM containing high K⁺ (25 mM KCl) for 72 hr and then switched to serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr. Cell injury was determined by mitochondrial metabolic activity (MTT reduction). Results are expressed as percentage of values from 25 mM K⁺-untreated control cells. Data are presented as mean \pm S.E.M of eight samples from duplicate experiments.

*p < 0.05 vs untreated control cells, #p < 0.05 vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 28 Effects of 24 hr pre-exposure with trolox on low-potassium-induced cell death in cultured cerebellar granule neurons.

Cultured cerebellar granule neurons were exposed to various concentrations of trolox (10-100 μ M) in serum-free DMEM containing high K⁺ (25 mM KCl) for 24 hr and then switched to serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr. Neuronal cell death was determined by quantifying the released LDH. Results are expressed as percentage of values from 25 mM K⁺-untreated control cells. Data are presented as mean \pm S.E.M of eight samples from duplicate experiments.

*p < 0.05 vs untreated control cells, #p < 0.05 vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 29 Effects of 48 hr pre-exposure with trolox on low-potassium-induced cell death in cultured cerebellar granule neurons.

Cultured cerebellar granule neurons were exposed to various concentrations of trolox (10-100 μ M) in serum-free DMEM containing high K⁺ (25 mM KCl) for 48 hr and then switched to serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr. Neuronal cell death was determined by quantifying the released LDH. Results are expressed as percentage of values from 25 mM K⁺-untreated control cells. Data are presented as mean \pm S.E.M of eight samples from duplicate experiments.

*p < 0.05 vs untreated control cells, #p < 0.05 vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 30 Effects of 72 hr pre-exposure with trolox on low-potassium-induced cell death in cultured cerebellar granule neurons.

Cultured cerebellar granule neurons were exposed to various concentrations of trolox (10-100 μ M) in serum-free DMEM containing high K⁺ (25 mM KCl) for 72 hr and then switched to serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr. Neuronal cell death was determined by quantifying the released LDH. Results are expressed as percentage of values from 25 mM K⁺-untreated control cells. Data are presented as mean \pm S.E.M of eight samples from duplicate experiments.

*p < 0.05 vs untreated control cells, #p < 0.05 vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 31 Effects of pre-exposure with geldanamycin on low-potassium-induced glutathione diminution in cultured cerebellar granule neurons

Cultured cerebellar granule neurons were exposed to various concentrations of 0.10 μ M GA in serum-free DMEM containing high K⁺ (25 mM KCl) for 24 hr and then switched to serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr after which cellular GSH contents were measured. Data represent mean \pm S.E.M values of eight samples.

*p < 0.05 vs untreated control cells, #p < 0.05 vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).




Fig. 32 Effects of pre-exposure with geldanamycin on low-potassium-induced lipid peroxidation in cultured cerebellar granule neurons.

Cultured cerebellar granule neurons were exposed to various concentrations of 0.10 μ M GA in serum-free DMEM containing high K⁺ (25 mM KCl) for 24 hr and then switched to serum-free DMEM containing low K⁺ (5 mM KCl) for 24 hr after which lipid peroxidation was measured by TBARS assay. Data represent mean \pm S.E.M values of eight samples.

* $p < 0.05$ vs untreated control cells, ** $p < 0.05$ vs low K⁺ (5 mM KCl) (one way ANOVA and Scheff's test).

CHAPTER V

DISCUSSION AND CONCLUSION

GA, an inhibitor of the HSP90 chaperone, has been reported to have several cellular effects, such as inhibition of v-src activity or destabilization of Raf-1 among others. Lopez-Maderuelo et al (2001) showed that GA treatment induces different phenotypes in different cell lines. In PC12 cells, it triggers apoptosis, whereas in the murine neuroblastoma N2A, it induces differentiation with neurite outgrowth. Mitogen-activated protein kinase activities ERK and JNK are activated differently according to cell type: in PC12 cells JNK is activated, and its inhibition abolishes apoptosis, but not ERK; in N2A cells, both ERK and JNK are activated, but with peak activities at different times.

Regarding to cell death, GA was reported to protect NRK-52E cells from okadaic acid-induced apoptosis, abrogated the overall okadaic acid-induced kinase activation, and specifically inhibited activation of p38 kinase by okadaic acid (Davis and Carbott, 1999). These results imply that decreased p38 activity and its cytosolic translocation together with cellular resistance to cytoskeletal disorganization may play a significant role in resistance to phosphorylation-dependent apoptosis. Recently, Sano (2001) found that GA at low doses (about 2 nM) appeared to be neurotrophic on DRG neurons in the presence or absence of neurotrophins, but higher doses of geldanamycin (> 5 nM) had severe cytotoxic effects on neurons. GA at low doses was also found to be neuroprotective against anti-cancer drugs. It was suggested that the neurotrophic effects of GA may be due to the association of GA with a member of the HSP90 family. Decreases in the levels of some specific protein(s) that requires HSP90 for its activity may interfere with various signal transduction pathways involving in cell injury and cell death.

As motivated by multimodal effects of GA on cell proliferation and differentiation, this study was designed to investigate a potential cytoprotective effect of GA against K⁺ deprivation-induced cell injuries in primary cultured rat cerebellar granule cells. It was initially hypothesized that GA might possess neuroprotective

effects, at least, *in vitro*. Apparently, experimental results from this study did support that speculation. It is notable that GA might exert remarkable neuroprotective effect if it had exposed to the neurons for a certain period prior to the insulting agent.

Effects of geldanamycin on cultured rat cerebellar granule cells and on low K^+ -induced neuronal injuries in these cells were investigated by using cell metabolic activity and viability, content of glutathione and lipid peroxidation, as the measuring endpoints. Eight-day cultured cerebellar granule cells were used in all experiments. Exposure of cultured cerebellar granule neurons for 12-72 hr to geldanamycin at different concentrations (0.01-1.0 μM) showed concentration- and exposure time-dependent neuroprotective effects. At low concentrations of GA with short incubation periods, GA showed a little effect on neuronal metabolic activity. However, after 24-72 hr pre-exposure to GA at concentrations higher than 0.05 μM , GA had a marked effect on neuronal metabolic activity. With 24 hr pre-exposure to GA at concentrations higher than 0.025 μM , cell death caused by low K^+ was significantly prevented. Apparently, the maximal magnitude of protection may be obtained from 24 hr pre-exposure to 0.10 μM GA.

Switching cultured neurons from medium containing 25 mM K^+ to medium containing 5 mM K^+ caused granule cell death mostly by apoptosis. Simultaneous exposure with GA and low K^+ for 24 h did not protect cell death. However, pretreatment of 0.1 μM GA in high K^+ condition for 24 h before subjecting to low K^+ condition effectively prevented granule cell death. Experimental results indicated that the cell survival rate was only approximately 50% after exposure to low K^+ for 24 h. In contrast, the cell survival rate was markedly enhanced up to that of cells maintained in high K^+ when pretreating with GA for a certain period of time. Furthermore, GSH assay revealed that total GSH content was reduced by nearly 40% after switching cultured neurons to low K^+ for 24 h. Pretreatment with 0.1 μM GA for 24 h effectively inhibited low K^+ -induced GSH diminution. Moreover, the same pretreatment with GA also prevented an increase in cellular lipid peroxidation after 24-h exposure to low K^+ . These findings suggest that GA pretreatment may prevent granule cell death by induction of proteins that regulate GSH metabolism and lipid peroxidation. In contrast, trolox, a soluble antioxidant compound which is pharmacological standard of this study for comparison, had no protection effect on low K^+ induced-injuries. Unchern et

al.(1997) found that trolox had no protection on low K^+ induced-injuries in cultured rat cerebellar granule neurons.

The highly conserved heat shock proteins (HSPs) accumulate in cells exposed to heat and a variety of other stressful stimuli including low K^+ condition. HSPs, which function mainly as molecular chaperones, allow cells to adapt to gradual changes in their environment and to survive in otherwise lethal conditions. The events of cell stress and cell death are linked and HSPs induced in response to stress appear to function at key regulatory points in the control of apoptosis. HSPs include antiapoptotic and proapoptotic proteins that interact with a variety of cellular proteins. Their expression level can determine the fate of the cell in response to a death stimulus, and apoptosis-inhibitory HSPs, in particular HSP27 and HSP70, may participate in carcinogenesis (Garrido et al., 2001).

GA, a 90-kDa heat shock protein (HSP90) specific inhibitor, is a well-known potential anticancer agent. Administration of GA to cells can rapidly and selectively inhibit the activities to HSP90 and of its substrates, thereby destabilizing client proteins. Its ability to simultaneously stimulate depletion of multiple oncogenic proteins suggests that GA may contribute to cancer therapy (Huang et al., 2002). The disruption of HSP 90 function that results from GA binding is likely to be responsible for many indirect effects of GA, including its ability to inhibit certain tyrosine kinases (Whitesell et al., 1994) and induce HSP70 expression (Conde et al., 1997).

In addition to inducing the activation of heat shock factor 1 (HSF1), GA increases the synthesis and cellular levels of heat shock proteins, particularly 70-kDa heat shock protein (HSP70). Conde et al. (1997) demonstrated that exposure of rat neonatal cardiomyocytes and H9c2 cells to GA induces heat shock proteins, thus providing protection against ischemic stress. These results suggest that GA may offer a pharmacological means of increasing the level of heat shock proteins in cardiac tissue and, in doing so, protecting the heart against ischemic/ reperfusion injury.

HSP 70 has been found to play a role in protection against apoptosis in several different cell types (Wei et al., 1995, Sato et al., 1996, Mosser et al., 1997). In addition, HSP70 appears to be responsible for the neuroprotective effects of heat

shock (Sato et al., 1996). Xiao et al. (1999) found that 0.1 $\mu\text{g/ml}$ GA effectively induced HSP 70 expression in HT22 cells.

Huang et al. (2002) found that GA inhibits trichostatin A-induced cell death and histone H4 hyperacetylation in COS-7 cells. The accumulated 70-kDa heat shock protein (HSP70) markedly increased up to 2 to 3 folds at 8 h in GA-treated cells, and the maximum amount up to 5 to 7 folds at 20 h. Conversely, HSP90 did not markedly increase in all treatments.

As an alternative explanation, based on a number of recent studies, it is possible that apoptotic cell death induced by low K^+ condition might be prevented by GA-induced increment of heat shock proteins, particularly HSP70.

The protective role of HSPs in cell death remains contentious. First, HSPs do not have the same protective ability in all apoptosis models. Second, some studies reveal no protective effects of HSPs in apoptosis at all, although these molecules are induced during apoptosis. Third, in some models, HSPs have been considered as apoptosis enhancers: overexpression of HSP70 enhances T-cell receptor/CD3- and Fas/Apo-1/ CD95-mediated apoptosis in Jurkat T cells, and overexpression of HSP90 increases the tumor necrosis factor (TNF)- α - and cycloheximide-induced apoptosis of the human U-937 cell line. Such conflicting data on HSP functions in apoptosis have been tentatively explained by the differential mechanisms used by distinct cells to respond to different apoptosis-inducing stimuli (Conde et al., 1997; Huang et al., 2002).

Recent findings suggest that unfolded or misfolded proteins participate in the pathology of several neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. Usually, several stress proteins and glial cells act as intracellular molecular chaperones and show chaperoning neuronal function, respectively. In the brains of patients with neurodegenerative disorders, however, stress proteins are expressed and frequently associated with protein aggregates, and glial cells are activated around degenerative regions. In addition, several stress proteins and glial cells may also regulate neuronal cell death and loss. Therefore, some types of stress proteins and glial cells are considered to be neuroprotective targets (Kitamura and Nomura, 2003; Pavlik et al, 2003). Therefore, it is conceivable to search for potential

substances which modulate stress protein and glial cell functions. This approach through which GA is a potential candidate may be a new therapeutic strategy to treat neurodegeneration (Parcellier et al, 2003; Sreedhar and Csermely, 2004).

In conclusion, experimental results in this study suggest that GA might possess a remarkable neuroprotective effect against K^+ deprivation-induced neuronal injury and death. GA pretreatment may prevent neuronal cell damages by induction of proteins that regulate GSH metabolism and cellular lipid peroxidation. In addition, GA may counteract with low K^+ -induced cell death because GA increases induction of HSPs, a group of potential factors to protect cells from damage.



สถาบันวิทยบริการ
จุฬาลงกรณ์มหาวิทยาลัย

REFERENCES

- Abbracchio, M. P., Ongini, E., and Memo, M. Disclosing apoptosis in the CNS. TiPS 20 (1999): 129-131.
- Akerboom, T. P. M., and Sies, H. Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Meth. Enzymol. 77 (1981): 373-382.
- Atlante, A., Gagliardi, S., Marra, E., and Calissano, P. Neuronal apoptosis in rats is accompanied by rapid impairment of cellular respiration and is prevented by scavengers of reactive oxygen species. Neurosci. Lett. 245 (1998): 127-130.
- Baker, M. A., Cerniglia, G. J., and Zaman, A. Microtiter plate assay for the measurement of glutathione and glutathione disulfide in large numbers of biological samples. Anal. Biochem. 190 (1990): 360-365.
- Bamberger, C. M., Wald, M., Bamberger, A., and Schulte, H. M. Inhibition of mineralocorticoid and glucocorticoid receptor function by the heat shock protein 90-binding agent geldanamycin. Mol. Cell. Endocrinol. 131 (1997): 233-240.
- Barres, B. A., Hart, I. K., Coles, H. S., Burne, J. F., Voyvodic, J. T., Richardson, W. D., and Raff, M. C. Cell death in the oligodendrocyte lineage. J. Neurobiol. 23 (1992): 1221-1230.
- Beere, H. M., and Green, D. G. Stress management—heat shock protein-70 and the regulation of apoptosis. TRENDS Cell Biol. 11 (2001): 6–10.
- Benčekroun, M. N., Schneider, E., Safa, A. R., Townsend, A. J., and Sinha, B. K. Benjamin, I. J., and McMillan, D.R. Stress (heat shock) proteins molecular chaperones in cardiovascular biology and disease. Circ. Res. 83 (1998): 117-132.

- Bisaglia, M., Natalini, B., Pellicciari, R., Straface, E., Monti, D., Franceschi, C., and Schettini, G. C₃-Fullero-*tris*-methanodicarboxylic acid protects cerebellar granule cells from apoptosis. J. Neurochem. 74 (2000): 1197-1204.
- Bouchard, L., Lamarre, L., and Tremblay, P. J. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57 (1989): 931-940.
- Bredesen, D. E. Neuronal apoptosis. Ann. Neurol. 3 (1995): 839-851.
- Bucci, M., Roviezzo, F., Cicala, C., Sessa, W. C., and Cirino, G. Geldanamycin, an inhibitor of heat shock protein 90 (HSP90) mediated signal transduction has anti-inflammatory effects and interacts with glucocorticoid receptor in vivo. Br. J. Pharmacol. 131 (2000): 13-16.
- Bukau, B., and Horwich, A. L. The HSP70 and HSP60 chaperone machines. Cell 90 (1998): 351-366.
- Burgoyne, R. D., Graham, M. E., and Cambray-Deakin, M. Neurotrophic effects of NMDA receptor activation on developing cerebellar granule cells. J. Neurocytol. 22 (1993): 689-695. [abstract]
- Buzzard, K., Giaccia, A., Killender, M., and Anderson, R. Heat shock protein 72 modulates pathway of stress-induced apoptosis. J. Biol. Chem. 273 (1998): 17147-17153.
- Carreras, C. W., Schirmer, A., Zhong, Z., and Santi D. V. Filter binding assay for the geldanamycin-heat shock protein 90 interaction. Anal. Biochem. 317 (2003): 40-46.
- Castagne, V., Gautschi, M., Lefevre, K., Posada, A., and Clarke, P. G. H. relationships between neuronal death and the cellular redox status. Focus on the developing nervous system. Prog. Neurobiol. 59 (1999): 397-423.
- Chalazonitix, A. and Fishbach, G. D. Elevated potassium induces morphological differentiation in dorsal root ganglionic neurons in dissociated cell culture. Dev. Biol. 78 (1980): 173-183.[abstract]

- Chan, P. H. Role of oxidants in ischemic brain damage. Stroke 27 (1996): 1124-1129.
- Chan, S. L., and Mattos, M. P. Caspase and calpain substrates: roles in synaptic plasticity and cell death. J. Neurosci. Res. 58 (1999): 167-190.[abstract]
- Chan, S. L., Tammariello, S. P., Estus, S., and Mattson, M. P. Prostate apoptosis response-4 mediates trophic factor withdrawal-induced apoptosis of hippocampal neurons: actions prior to mitochondrial dysfunction and caspase activation. J. Neurochem. 73 (1999): 502-512.
- Chavany, C., Mimnaugh, E., Miller, P., Bitton, R., Nguyen, P., Trepel, J., Whitesell, L., Schnur, R., Moyer, J.D., and Neckers, L. GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185 (erbB92). J. Biol. Chem. 271 (1996): 4974-4977.
- Chen, H., Singh, S., and Perdew, G. H. The Ah receptor is a sensitive target of geldanamycin induced protein turnover. Arch. Biochem. Biophys. 348 (1997): 190-198.
- Choi, D. W. Ischemia-induced neuronal apoptosis. Curr. Opin. Neurobiol. 8 (1996): 667-672.
- Claycombe, K. J., and Meydani, S. N. Vitamin E and genome stability. Mutation Res. 475 (2001): 37-44.
- Condeelis, A. G., Lau, S. S., Dillmann, W. H., Mestril, R. Induction of heat shock proteins by tyrosine kinase inhibitors in rat cardiomyocytes and myogenic cells confers protection against simulated ischemia. J. Mol. Cell. Cardiol. 29 (1997): 1927-38.
- Costa, L. G. Signal transduction in environmental neurotoxicity. Annu. Rev. Pharmacol. Toxicol. 38 (1998): 21-43.
- Cotman, C. W. and Anderson, A. J. A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol. Neurobiol. 10 (1995): 19-45.
- Coyle, J. T. and Puttfarcken, P. Oxidative stress, glutamate and neurodegenerative disorders. Science 262 (1993): 689-695.

- Cruz-Aguado, R., Francis-Turner, L., Diaz, C. M., and Antunez, I. Quinolinic acid lesion induces changes in rat striatal glutathione metabolism. Neurochem. Inter. 37 (2000): 53-60.
- Cull-Candy, S. G., Howe, J. R., and Ogden, D. C. Noise and single channels activated by excitatory amino acids in rat cerebellar granule neurons. J. Physiol. (Lond.) 400 (1988): 189-222. [abstract]
- Cuzzocrea, S., Riley, D. P., Caputi, A. P., and Salvemini, D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol. Rev. 53 (2001): 135-159.
- D'Mello, S., Aglieco, F., Roberts, M. R., Borodezt, K., and Haycock, J. W. A DEVD-inhibited caspase other than CPP32 is involved in the commitment of cerebellar granule neurons to apoptosis induced by K⁺ deprivation. J Neurochem. 70(1998): 1809-1818.
- D'Mello, S. R., Galli, C., Ciotti, T., and Calissano, P. Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin-like growth factor I and cAMP. Proc. Natl. Acad. Sci. 90 (1993): 10989-10993.
- Dasgupta, G., and Momand, J. Geldanamycin prevent nuclear trans-location of mutant p53. Exper. Cell Res. 237 (1997): 29-37.
- Davis, M. A., and Carbott, D. E. Herbimycin A and geldanamycin inhibit okadaic acid-induced apoptosis and p38 activation in NRK-52E renal epithelial cells. Toxicol. Appl. Pharmacol. 161 (1999): 59-74.
- Davis, M. A., and Carbott, D. E. Herbimycin A and Geldanamycin Inhibit Okadaic Acid-Induced Apoptosis and p38 Activation in NRK-52E Renal Epithelial Cells. Toxicol. Appl. Pharmacol. 161 (1999): 59-74.
- DeBoer, C., Meulman, P. A., Wnuk, R. J., and Peterson, D. H. Geldanamycin. J. Antibiot. (Tokyo) 23 (1970): 442-447.

- Dikalov, S., Landmesser, U., and Harrison, D. G. Geldanamycin leads to superoxide formation by enzymatic and non-enzymatic redox cycling. J. Biol. Chem. 277 (2002): 25480-25485.
- Franklin, J. L. and Johnson, E. M. Suppression of programmed neuronal death by sustained elevation of cytoplasmic calcium. Trends Neurosci. 15 (1992): 501-508. [abstract]
- Galea-Lauri, J., Richardson, A. J., Latchman, D. S., and Katz, D. R. Increased heat shock protein 90 (HSP 90) expression leads to increased apoptosis in the monoblastoid cell line U937 following induction with TNF- α and cycloheximide. J. Immunol. 157 (1996): 4109-4118.
- Galli C., Meucci O., Scorziello, A., Werge, T. M., Calissano, P., and Schettini, G. Apoptosis in cerebellar granule cells is blocked by high KCl. Forskolin and IGF-1 through distinct mechanism of actionL the involvement of intracellular calcium and RNA synthesis. J. Neurosci. 15 (1995): 1172-1179.
- Gallo, V., Biovanini, C., and Levi, G. Modulation of non-Nmethyl-D-aspartate receptors in cultured cerebellar granule cell. J. Neurochem. 54 (1990): 1619-1625.
- Gallo, V., Kingsbury, A., Balazs, R., and Jorgensen, O. S. The role of depolarization in the survival and differentiation of cerebellar granule cells in culture. J. Neurosci. 7 (1987): 2203-2213.
- Garrido, C., Gurbuxani, S., Ravagnan, L., Guido Kroemer, G. Heat Shock Proteins: Endogenous Modulators of Apoptotic Cell Death. Biochem. Biophys. Res. Comm. 286 (2001): 433-442.
- Gilmore, R., Coffey, M. C., and Lee, P. W. Active participation of HSP90 in the biogenesis of the trimeric reovirus cell attachment protein $\sigma 1$. J. Biol. Chem. 273 (1998): 15227-152333.
- Gleichmann, M., Weller, M., and Schulaz, J. B. Insulin-like growth factor-1-mediated protection from neuronal apoptosis is linked to phosphorylation of the pro-

apoptotic protein BAD but not to inhibition of cytochrome c translocation in rat cerebellar granule neurons. *Neurosci Lett.* 282 (2000): 69-72.

Good, P. F., Werner, P. Hsu, A., Olanow, C. W. and Perl, D. P. Evidence for neuronal oxidative damage in Alzheimer's disease. *Am. J. Pathol.* 149 (1996): 21-28.

Grenert, J. P., Sullivan, W. P., Fadden, P., Haystead, T. A. J., Clark, J., Mimnaugh, E., Krutzsch, H., Ochel, H., Schulte, T. W., Sausville, E., Neckers, L. M., and Toft, D. O. The amino-terminal domain of heatshock protein 90 (HSP90) that binds geldanamycin is an ATP/ADP switch domain that regulates HSP90 conformation. *J. Biol. Chem.* 272 (1997): 23843-23850.

Grisham, M. B. A radical approach to treating inflammation. *TiPs* 21 (2000): 119-120.

Guo, Q., Fu, W., Xie, J., Luo, H., Sells, S. F., Geddes, J. W., Bondada, V., Rangnekar, V., and Mattson, M. pPar-4 is a novel mediator of neuronal degeneration associated with the pathogenesis of Alzheimer's disease. *Nature Med.* 4 (1998): 957-962.[abstract]

Hansen, M. B., Nielsen, S. E., and Berg, K. RE-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. *J. Immunol. Methods* 119 (1989): 203-210.

Hockberger, P. E., Tseng, H. Y., and Connor, J. A. Immunocytochemical and electrophysiological differentiation of rat cerebellar granule cells in explant cultures. *J. Neurosci.* 7 (1987): 1370-1383.[abstract]

Hockenbery, D., Oltvai, Z. N., Yin, X. M., Milliman, C., and Korsmeyer, S. J. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. *Cell* 75 (1993): 241-251.

Horikoshi, T., and Sakakibara, M. Quantitation of relative mRNA expression in rat brain using simple RT-PCR and ethidium bromide stain. *J. Neurosci. Methods* 99 (2000): 45-51.

- Huang, H., Liu, Y., Liu, S., Tzang, B., and Lee, W. Geldanamycin inhibits trichostatin A-induced cell death and histone H4 hyperacetylation in COS-7 cells. Life Sci. 70 (2002): 1763-1775.
- Huang, H-C., Liu, Y-C., Liu, S-H., Tzang, B-S., Lee, W-C. Geldanamycin inhibits trichostatin A-induced cell death and histone H4 hyperacetylation in COS-7 cells. Life Sci. 70 (2002): 1763-1775.
- Isaev, N. K., Stelmashook, E. V., Halle, A., Harm, C., Lautenschlager, M., Weih, M., Dirnagl, U., Victorov, I. V., and Zorov, D. B. Inhibition of Na^+ , K^+ -ATPase activity in cultured rat cerebellar granule cells prevents the onset of apoptosis induced by low potassium. Neurosci. Lett. 283 (2000): 41-44.
- Ishida, I. And Deguchi, T. Effect of depolarizing agents on choline acetyltransferase and acetylcholine transferase activities in primary cell cultures of spinal cord. J. Neurosci. 3 (1983): 1818-1823.[abstract]
- Itoh, H., Ogura, M. Komatsuda, A., Wakui, H., Miura, A. B., and Tashima, Y. A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90. Biochem. J. 343 (1999): 697-703.
- Johnson, J. L., and Toft, D. O. Binding of p23 and HSP90 during assembly with the progesterone receptor. Mol. Endocrinol. 9 (1995): 670-678.[abstract]
- Joly, G. A., Ayres, M., and Kilbourn, R. G. Potent inhibition of inducible nitric oxide synthase by geldanamycin, a tyrosine kinase inhibitor, in endothelial, smooth muscle cells, and rat aorta. FEBS Lett. 403 (1997): 40-44.
- Kitamura, Y., Nomura, Y. Stress proteins and glial functions: possible therapeutic targets for neurodegenerative disorders. Pharmacol. Ther. 97 (2003): 35-53.
- Knusel, B., Burton, L. E., Longo, F. M., Mobley, W. C., Koliatsos, V. E., Price, D. L., and Hefti, F. Trophic actions of recombinant human nerve growth factor on cultured rat embryonic CNS cells. Exp. Neurol. 110 (1990): 274-283.[abstract]
- Koike, T., Martin, D. P., and Johnson, E. M. Role of Ca^{2+} Channels in the ability of membrane depolarization to prevent neuronal death induced by trophic-factor

- deprivation: evidence that levels of internal Ca^{2+} determine nerve growth factor dependence of sympathetic ganglion cells. Proc. Natl. Acad. Sci. 86 (1989): 6421-6425.[abstract]
- Kruman, I., Bruce-Keller, A. J., Bredesen, D. W. G. and Mattson, M. P. (1997) Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J. Neurosci. 17(1997): 5089-5100.[abstract]
- Kuduk, S. D., Zheng, F. F., Sepp-Lorenzino, L., Rosen, N., and Danishfsky, S. J. Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg. Med. Chem. Lett. 9 (1999): 1233-1238.
- Kunimoto, M. Methylmercury induces apoptosis of rat cerebellar neurons in primary culture. Biochem. Biophys. Res. Commun. 204 (1994): 310-317.[abstract]
- Lai, M., Huang, K., Chang, W., and Lai, Y. Geldanamycin induction of grp78 requires activation of reactive oxygen species via ER stress responsive elements in 9L rat brain tumour cells. Cell. Signal. 15 (2003): 585-595.
- Lasher, R. S., and Zagon, I. S. The effect of potassium on neuronal differentiation in cultures of dissociated newborn rat cerebellum. Brain Res. 41(1972): 482-488.
- Lauritzen, I., Zanzouri, M., Honore, E., Duprat, F., Ehrenguber, M. U., Lazdunski, M., and Patel, A.J. K^+ -dependent cerebellar granule neuron apoptosis. J. Biol. Chem. 278 (2003): 32068-32076.
- Lawrence, C. W., Gibbs, P. E., Murante, R. S., Wang, X. D., Li, Z., Memanus, T. P., McGregor, W. G., Nelson, J. R., Hinkle, D. C., and Maher, V. M. Roles of DNA polymerase zeta and Rev1 protein in eukaryotic mutagenesis and translation replication. Cold Spring Harb. Symp. Quant. Biol. 65 (2000): 61-69.[abstract]
- Levi, G., Aloisi, F., Ciotti, M. T., and Gallo, M. T. Autoradiographic localization and depolarization-induced release of acidic amino acids in differentiating cerebellar granule cell cultures Brain Res. 280 (1984): 77-86.

- Liu, F., and Ng, T. B. Antioxidative and free radicle scavenging activities of selected medicinal herbs. Life Sci. 66 (2000): 725-735.
- Liu, H., Lightfoot, R., and Stevens, J. L. Activation of heat shock factor by alkylating agents is triggered by glutathione depletion and oxidation of protein thiols. J. Biol. Chem. 271 (1996): 4805-4812.
- Lobner, D. Comparison of the LDH and MTT assays for quantifying cell death: validity for neuronal apoptosis. J. Neurosci. Meth. 96 (2000): 147-152.
- Lopez-Maderuelo, M. D., Fernandez-Renart, M., Moratilla, C., Renart, J. Opposite effects of the HSP90 inhibitor geldanamycin: induction of apoptosis in PC12, and differentiation in N2A cells. FEBS Lett. 490 (2001): 23-27.
- Lu, A., Ran, R., Parmentier-Batteur, S., Nee, A., and Sharp, F. R. Geldanamycin induces heat shock proteins in brain and protects against focal cerebral ischemia. J. Neurochem. 81 (2002): 355-364.
- Mabjeesh, N. J., Post, D. E., Willard, M. T., Kaur, B., Van Meir, E. G., Simons, J. W., and Zhong, H. Geldanamycin induces degradation of hypoxia-inducible factor 1 α protein via the proteosome pathway in prostate cancer cells. Cancer Res. 62 (May 2002): 2478-2482.
- Maher, P. and Davis, J.B. The role of monoamine metabolism in glutamate toxicity. J. Neurosci. 16 (1996): 6394-6401.
- Malhotra, V., Shanley, T. P., Pittet, J. F., Welch, W. J., and Wong, H. R. Geldanamycin inhibits NF-kappaB activation and interleukin-8 gene expression in cultured human respiratory epithelium. Am. J. Respir. Cell Mol. Biol. 25 (2001): 92-97.
- Maloney, A., and Workman, P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Experi. Opin. Biol. Ther. 2(1) (2002): 3-24.
- Mattson, M. P. Modification of ion homeostasis by lipid peroxidation: roles in neuronal degeneration and adaptive plasticity. Trends Neurosci. 21 (1998): 53-57.[abstract]

- Mattson, M. P., Culmsee, C., and Yu, Z. F. Apoptotic and antiapoptotic mechanisms in stroke. Cell Tissue Res. 301 (2000): 173-187.
- Mattson, M. P., Keller, J. N., and Begley, J. G. Evidence for synaptic apoptosis. Exp. Neurol. 153 (1998): 35-48.
- Miller, T. M. and Johnson, E. M. Jr. Metabolic and genetic analyses of apoptosis in potassium/serum-deprived rat cerebellar granule cells. J. Neurosci. 16 (1996): 7487-7495.
- Miyata, Y., and Yahara, I. The 90-kDa heat shock protein, HSP90, binds and protects casein kinase II from self-aggregation and enhances its kinase activity. J. Biol. Chem. 267 (1992): 7042-7047.
- Mossmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1993): 55-63.
- Munster, P. N., Srethapakdi, M., Moasser, M. M., and Rosen, N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res. 61 (2001): 2945-2952.
- Murphy, P., Sharp, A., Shin, J., Gavrilyuk, V., Dello Russo, C., and Weinberg, G. Suppressive effects of ansamycins on inducible nitric oxide synthase expression and the development of experimental autoimmune encephalomyelitis. J. Neurosci. Res. 67 (February 2002): 461-70.
- Nardi, N., Avidan, G., Daily, D., Zilkha-Falb, R., and Barzilai, A. Biochemical and temporal analysis of events associated with apoptosis induced by lowering the extracellular potassium concentration in mouse cerebellar granule neurons. J. Neurochem. 68 (1997): 750-759.
- Nath, R., McGinnis, K., Dutta, S., Shivers, B., and Wang, K. K. W. Inhibition of p38 kinase mimics survival signal-linked protection against apoptosis in rat cerebellar granule neurons. Cell. Mol. Biol. Lett. 6 (2001): 173-184.

- Nath, R., Raser, K.J., Stafford, D., Hajimohammadreza, I., Posner, A., Allen, H., Talanian, R. V., Yuen, P., Bilbertsen, R. B. and Wang, K. K. Non-crythroid alpha-spectrin breakdown by calpain and interleukin 1betaconverting-enzyme-like protease(s) in apoptotic cells: contributory roles of both protease families in neuronal apoptosis, Biochem. J. 319 (1996): 683-690.
- Neame, S. J., Rubin, L. L., and Philpott, K. L. Blocking cytochrome C activity within intact neurons inhibits apoptosis. J. Cell. Biol. 142 (1998): 1583-1593.
- Neckers, L. M. Can the heat shock protein 90 inhibitor geldanamycin be designed to specifically inhibit HER-2 tyrosine kinase? Drug Resist. Updat. 3 (2000): 203-205.
- Ochel, H., Schulte, T. W., Nguyen, P., Trepel, J., and Neckers, L. The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase. Mol. Genet. Metab. 66 (1999): 24-30.
- Ohkawa, H., Ohishi, N., and Yagi, K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95 (1979): 351-358.
- Olanow, C. W. A radical hypothesis for neurodegeneration. TINS 16 (1993): 439-444.
- Oppenheim, R. W. Cell death during development of the nervous system. Annu. Rev. Neurosci. 14 (1991): 453-501.[abstract]
- Pai, K. S., and Cunningham, D.D. Geldanamycin specifically modulates thrombin-mediated morphological changes in mouse neuroblasts. J. Neurochem. 80 (2002): 715-718.
- Parcellier, A., Gurbuxani, S., Schmitt, E., Solary, E., Garrido, C. Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways. Biochem. Biophys. Res. Comm. 304 (2003):505–512.
- Pavlik, A., Aneja, I. S., Lexa, J., Al-Zoabi, B. A. Identification of cerebral neurons and glial cell types inducing heat shock protein HSP70 following heat stress in the rat. Brain Res. 973 (2003): 179–189.

- Persons, D. L., Yazlovitskaya, E. M., Cui, W., and Peling, J. C. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells' inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin. Cancer Res. 5 (1999): 1007-1014.
- Piper, P. W. The HSP90 chaperone as a promising drug target. Curr. Opin. Investig. Drugs 2 (2001): 1606-1610.
- Portera-Cailliau, C., Hedreen, J. C., Price, D. L., and Koliatsos, V. E. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J. Neurosci. 15 (1995): 3775-3787.
- Pritchard, K. A. J., Ackerman, A. W., Gross, E. R., Stepp, D. W., Shi, Y., Fontana, J. T., Baker, J. E., and Sessa, W. C. Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric-oxide synthase. J. Biol. Chem. 276 (2001): 17621-17624.[abstract]
- Putcha, G. V., Deshmukh, M., and Johnson E. M. J. BAX translocation is a critical event in neuronal apoptosis: regulation by neuroprotectants, Bcl-2, and caspases. J. Neurosci. 19 (1999): 7476-7485.
- Rabizadeh, S., Gralla, E. B., Borchelt, D. R., Gwinn, R., Velentine, J. S., Sisodia, S., Wong, P., Lee, M., Hahn, H., and Bredesen, D. E. Mutations associated with amyotrophic lateral sclerosis convert superoxide dismutase from an antiapoptotic gene to a proapoptotic gene: studies in yeast and neural cells. Proc. Natl. Acad. Sci. 92 (1995): 3024-3028.[abstract]
- Raff, M. C., Barres, B. A., Burne, J. F., Coles, H. S., Ishizaki, Y., and Jacobson, M. D. Programmed cell death and the control of cell survival: lessons from the nervous system. Science 262 (1993): 695-700.
- Reiter, R. J. Oxidative damage in the central nervous system: protection by melatonin. Prog. Neurobiol. 56 (1998): 359-384.
- Resink, A., Boer, G. J., and Balazs, R. Treatment with excitatory amino acids or high K^+ and NMDA receptors in cerebellar granule cells. Neuroreport 3 (1992): 747-760.[abstract]

- Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., and Pearl, L. H. Structural basis for inhibition of HSP90 molecular chaperone by the antitumor antibiotics radicicol and Geldanamycin. J. Med. Chem. 28 (1999): 260-266.
- Roy, N., Mahadevan, M. S., Mclean, M., Shutler, G., Yaraghi, Z., Farahani, R., Baird, S., Esner-Johnston, A., Lefebvre, C., Kang, X., Salih, M., Huguet, A., Tamai, K., Guan, X., Loannou, P., Crawford, T. O., de Jong, P. J., Surth, L., Ikeda, J.-E., Korneluk, R. G., and Mackenzie, A. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 80 (1995): 167-178.
- Sano, M. Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drugs on cultured embryonic sensory neurons. Neuropharmacol. 40 (2001): 947-953.
- Sarin Tadtong. Secondary metabolites of mangrove *Streptomyces* sp. TRA 9875-2. Master's Thesis, Department of Chemistry. Graduate School, Chulalongkorn University, 2000.
- Sasaki, K., Yasuda, H., and Onodera, K. Growth inhibition of virus transformed cells in vitro and antitumor activity in vivo of geldanamycin and its derivatives. J. Antibiot. (Tokyo) 32 (1979): 849-851. [abstract]
- Sastry, P. S., and Rao, K. S. Apoptosis and nervous system. J. Neurochem. 74 (2000): 1-20.
- Scheibel, T., and Buchner, J. The HSP90 complex—a super-chaperone machine as a novel drug target. Biochem. Pharmacol. 56 (1998): 675-681.
- Schulte, T. W., Akinaga, S., Murakata, T., Agatsuma, T., Sugimoto, S., Nakano, H., Lee, Y. S., Simen, B. B., Argon, Y., Toft, D. O., Neckers, L. M., and Sharma, S. V. Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperon. Mol. Endocrinol. 13 (1999): 1435-1448.
- Schulte, T. W., Akinaga, S., Soga, S., Sullivan, W., Stensgard, B., Toft, D., and Neckers, L. M. Antibiotic radicicol binds to the N-terminal domain of HSP90, and shares important biologic activities with geldanamycin. Cell Stress Chaperones 3 (1998): 100-108.

- Schulte, T. W., An, W. G., and Neckers, L. M. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem. Biophys. Res. Commun. 239 (1997): 655-659.
- Schulz, J., Beinroth, S., Weller, M., Wullner, U., and Klockgether, T. Endonucleolytic DNA fragmentation is not required for apoptosis of cultured rat cerebellar granule neurons. Neurosci Lett. 245 (1998): 9-12.[abstract]
- Segnitz, B., and Gehring, U. The function of steroid hormone receptors is inhibited by the HSP90-specific compound geldanamycin. J. Biol. Chem. 272 (1997): 18694-18701.
- Seu, J., Ku, H., Tseng, W., Chen, M., Tsai, L., and Huang, Y. Determination of thiobarbituric acid adduct of malondialdehyde using on-line microdialysis coupled with high-performance liquid chromatography. Anal. Sci. 19 (2003): 621-624.
- Shastry, S., and Joyner, M. J. Geldanamycin attenuates NO-mediated dilation in human skin. Am. J. Physiol. Heart Circ. Physiol. 282 (2002): H232-236.[abstract]
- Shimoke, K., Yamada, M., Ikeuchi, T., and Hatanaka, H. Synthetic lipid products of PI3-kinase which are added to culture medium prevent low K⁺-induced apoptosis of cerebellar granule neurons via Akt kinase activation. FEBS Lett. 437 (1998): 221-224.
- Shulz, J. B., Weller, M., and Klockgether, T. Potassium deprivation-induced apoptosis of cerebellar granule neurons: A sequential requirement for new mRNA and protein synthesis, ICE-like protease activity, and reactive oxygen species. The J. Neurosci. 16 (1996): 4696-4706.
- Sittler, A., Lurz, R., Lueder, G., Priller, J., Lehrach, H., Hayer-Hartl, M. K., Hartl, F. U., and Wanker, E. E. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet. 10 (2001): 1719.

- Skaper, S. D., Floreani, M., Nepro, A., Facci, L., and Giusti, P. Neurotrophins rescue cerebellar granule neurons from oxidative stress-mediated apoptotic death: selective involvement of phosphatidylinositol 3-kinase and the mitogen-activated protein kinase pathway. J. Neurochem. 7 (1998): 1859-1865.
- Smith, D. F., Whitesell, L., Nair, S. C., Chen, S. Y., Prapapanich, V., and Rimerman, R. A. Progesterone receptor structure and function altered by geldanamycin, an HSP90-binding agent. Mol. Cell. Biol. 15 (1995): 6804-6812.
- Smith, M. A., Rottkamp, C. A., Nunomura, A., Raina, A. K., and Perry, G. Oxidative stress in Alzheimer's disease. Biochim. Biophys. Acta. 1502 (2000): 139-144.
- Sreedhar, A. S., Csermely, P. Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy. A comprehensive review. Pharmacol. Ther. 101 (2004): 227– 257.
- Stancato, L. F., Silverstein, A. M., Owens-Grillo, J. K., Chow, Y., Jove, R., and Pratt, W. B. The HSP90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase. J. Biol. Chem. 272 (1997): 4013-4020.
- Stebbins, C. E. et al. Structure of geldanamycin in heat shock protein chaperone complex. Cell 89 (1997): 239-250.
- Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., and Pavletich, N. P. Crystal structure of an HSP90-Geldanamycin complex' targeting of a protein chaperone by an antitumor agent. Cell 89 (1997): 239-250.
- Stoof, J. C., Winogrodzka, A., van Muiswinkel, F. L., Wolters, E. C., Voorn, P., Groenewegen, H. J., Booij, J., and Drukarch, B. Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy. Eur. J. Pharmacol 375 (1999): 75-78.
- Storch, A., Burkhardt, K., Ludolph, A. C., and Schwarz, J. Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism. J. Neurochem. 75 (2000): 2259-2569.

- Storey, K. B. Oxidative stress: animal adaptations in nature. Braz. J. Med. Biol. Res. 29 (1996): 1715-1733.
- Suttitanamongkol, S., Gear, A. R. L., and Polanowska-Grabowska, R. Geldanamycin disrupts platelet-membrane structure, leading to membrane permeabilization and inhibition of platelet aggregation. Biochem. J. 345 (2000): 307-314.
- Szanto, S., Csermely, P., Kovacs, I., Csongor, J., Illes, A., Bako, G., Szegedi, G., and Sipka, S. Inhibition of arachidonic acid release from human peripheral mononuclear cells by heat shock treatment and geldanamycin. Immunol. Lett. 83 (2002): 181-185.
- Tan, S., Sagara, Y., Liu, Y., Maher, P., and Schubert, D. The regulation of reactive oxygen species production during programmed cell death. J. Cell Biol. 141 (1997a): 1423-1432.
- Taylor, J., Gatchalian, C. L., Keen, G., and Rubin, L. L. Apoptosis in cerebellar granule neurones: involvement of interleukin-1 β converting enzyme-like proteases. J. Neurochem. 68 (1997): 1598-1605.
- Thomas, L. P., Godin, D. V., and Hansen, S. Parkinson's disease: A disorder due to nigral glutathione deficiency? Neuroscience Lett. 33 (1982): 305-310.
- Tietze, F. Enzymic method of quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal. Biochem. 27 (1969): 502-522.
- Trotter, L., Panton, W., Hajimohamadreza, I., Petalidis, L., Ward, R., Flemming, Armstrong C. G., Cohen, P., Karran, E. H., and Kinloch, R. A. Mitogen-activated protein kinase kinase 7 is activated during low potassium-induced apoptosis in rat cerebellar granule neurons. Neurosci. Lett. 320 (2002): 29-32.
- Unchern, S., Nagata, K., Saito, H., and Fukada, J. Piperine, a pungent alkaloid, is cytotoxic to cultured neurons from the embryonic rat brain. Biol. Pharm. Bull. 17 (1994a): 403-406.

- Unchern, S., Nagata, K., Saito, H., and Fukada, J. Reduction of neurite extension by piperine, examined on hippocampal and septal neurons in serum-free cultures. Biol. Pharm. Bull 17 (1994b): 898-901.
- Unchern, S., Nagata, K., Saito, H., and Fukada, J. Selectivity cytotoxicity of piperine on cultured rat hippocampal neurons in comparison with cultured astrocytes: the possible involvement of lipid peroxidation. Biol. Pharm. Bull 20 (1997): 958-961.
- Uryu, S., Harada, J., Hisamoto, M., and Oda, T. Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons. Brain Res. 924 (2002): 229-236.
- Vasilevskaya, I. A., and O'Dwyer, P. J. Effects of geldanamycin on signaling through activator-protein 1 in hypoxic HT29 human colon adenocarcinoma cells. Cancer Res. 59 (1999): 3935-3940.
- Vaudry, D., Falluel-Morel, A., Leuillet, S., Vaudry, H., and Gonzalez, B. Regulators of cerebellar granule cell development act through specific signaling pathways. Science 300 (2003): 1532-1533.
- Verity, M. A., Introduction: A coming of age for molecular neurotoxicology. Brain Pathol. 12 (2002): 472-474.
- Wallin, B., Rosengren, B., Shertzer, H. G., and Camejo, G. Lipoprotein oxidation and measurement of thiobarbituric acid reacting substances formation in a single microtiter plate: its use for evaluation of antioxidants. Anal. Biochem. 208 (1993): 10-15.
- Wang, W., and Dow, K. E., Quantitative analysis of mRNA expression of neuron-specific growth-associated genes in rat primary neurons by competitive RT-PCR. Brain Res. Protocols 2 (1998): 199-208.
- Watson, A., Eilers, A., Lallemand, D., Kyriakia, J., Rubin, L.L., and Ham, L. Phosphorylation of c-Jun is necessary for apoptosis induced by survival signal withdrawal in cerebellar granule neurons. J. Neurosci. 18 (1998): 751-762.

- Webb, C. P., Hose, C. D., Koochekpour, S., Jeffers, M., Oskarsson, M., Sausville, E., Monks, A., and Vande Woude, G. F. The geldanamycin are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res. 60 (2000): 342-349.
- White, M. J., DiCaprio, M. J., and Greenberg, D. A. Assessment of neuronal viability with Alamer blue in cortical and granule cell cultures. J. Neurosci. Methods 70 (1996): 195-200.
- Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E. and Neckers, L. M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. 91(1994): 8324-8328.[abstract]
- Whitesell, L., Sutphin, P. D., Pulcini, E. J., Martinez, J. D., and Cook, P. H. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamyci, an HSP90-binding agent. Mol. Cell. Biol. 18 (1998): 1517-1524.
- Wood, K. A., Dipasquale, B., and Youle, R. J. In situ labeling of granule cells for apoptosis-associated DNA fragmentation reveals different mechanisms of cell loss in developing cerebellum. Neuron 11(1993): 621-632.[abstract]
- Workman, P., and Maloney, A. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert. Opin. Biol. Ther. 2 (2002): 3-24.
- Xiao, N., Callaway, C. W., Lipinski C. A., Hicks, S. D., and DeFranco, D. B. Geldanamycin provides posttreatment protection against glutamatinduced oxidative toxicity in a mouse hippocampal cell line. J. Neurochem. 72 (1999): 95-101.
- Yagi, K. Simple procedure for specific assay of lipid hydroperoxides in serum or plasma. Free Radic. Antioxidant Protocols 108 (1998): 101-106.[abstract]

Yamaki, H., Suzuki, H., Choi, E. C., and Tanaka, N. Inhibition of DNA synthesis in murine tumor cells by geldanamycin, an antibiotic of the benzoquinoid ansamycin group. J. Antibiot. (Tokyo) 35 (1982): 886-892. [abstract]

Yorgin, P. D., Hartson, S. V., Fella, A. M., Scrogins, B. T., Huang, W., Katsanis, E., Couchman, J. M., Matts, R. L., and Whitesell, L. Effects of geldanamycin, a heat-shock protein 90-binding agent on T cell function and T cell nonreceptor protein tyrosine kinases. J. Immunol. 164 (2000): 2915-2923.



สถาบันวิทยบริการ
จุฬาลงกรณ์มหาวิทยาลัย



APPENDICES

สถาบันวิทยบริการ
จุฬาลงกรณ์มหาวิทยาลัย

1. Effects of geldanamycin on MTT reduction in cultured cerebellar granule neurons

Table 1.1 : 12 hr of incubation

| | Control | 0.01 μ M | 0.05 μ M | 0.1 μ M | 0.5 μ M | 1 μ M |
|---------|---------|--------------|--------------|-------------|-------------|-----------|
| Group 1 | 100 | 109.90 | 107.26 | 107.26 | 109.29 | 96.90 |
| Group 2 | 100 | 115.99 | 105.23 | 105.23 | 102.79 | 97.71 |
| Group 3 | 100 | 110.51 | 102.79 | 102.79 | 98.73 | 93.85 |
| Group 4 | 100 | 100.15 | 106.45 | 106.45 | 102.99 | 92.64 |
| Group 5 | 100 | 101.49 | 99.03 | 99.03 | 98.68 | 92.01 |
| Group 6 | 100 | 98.68 | 100.44 | 100.44 | 90.61 | 86.39 |
| Group 7 | 100 | 92.01 | 96.22 | 96.22 | 88.49 | 83.23 |
| Group 8 | 100 | 96.93 | 94.82 | 94.82 | 88.15 | 86.39 |
| Mean | 100 | 103.21 | 101.53 | 101.53 | 97.47 | 91.14 |
| S.E.M | 0 | 2.86 | 1.99 | 1.65 | 2.73 | 1.86 |

Table 1.2 : 24 hr of incubation

| | Control | 0.01 μ M | 0.05 μ M | 0.1 μ M | 0.5 μ M | 1 μ M |
|---------|---------|--------------|--------------|-------------|-------------|-----------|
| Group 1 | 100 | 107.00 | 113.56 | 114.61 | 110.98 | 104.24 |
| Group 2 | 100 | 104.24 | 113.92 | 111.49 | 110.97 | 104.06 |
| Group 3 | 100 | 102.43 | 107.10 | 102.17 | 91.41 | 93.92 |
| Group 4 | 100 | 104.33 | 107.97 | 107.97 | 104.58 | 93.07 |
| Group 5 | 100 | 106.94 | 97.69 | 108.65 | 94.43 | 95.97 |
| Group 6 | 100 | 103.34 | 116.53 | 103.17 | 86.72 | 87.96 |
| Group 7 | 100 | 101.79 | 105.23 | 102.49 | 88.39 | 86.09 |
| Group 8 | 100 | 102.24 | 102.23 | 111.61 | 84.49 | 90.32 |
| Mean | 100 | 104.04 | 108.03 | 107.77 | 96.49 | 94.46 |
| S.E.M | 0 | 0.72 | 2.26 | 1.67 | 3.83 | 2.39 |

Table 1.3 : 48 hr of incubation

| | Control | 0.01 μ M | 0.05 μ M | 0.1 μ M | 0.5 μ M | 1 μ M |
|---------|---------|--------------|--------------|-------------|-------------|-----------|
| Group 1 | 100 | 101.53 | 92.79 | 109.49 | 104.69 | 91.27 |
| Group 2 | 100 | 97.76 | 90.95 | 92.54 | 89.08 | 75.17 |
| Group 3 | 100 | 101.02 | 118.17 | 116.39 | 105.16 | 101.12 |
| Group 4 | 100 | 108.97 | 115.52 | 113.33 | 106.44 | 103.97 |
| Group 5 | 100 | 96.10 | 96.47 | 96.47 | 81.15 | 85.98 |
| Group 6 | 100 | 108.91 | 93.78 | 106.78 | 84.78 | 98.05 |
| Group 7 | 100 | 116.03 | 106.78 | 93.78 | 87.89 | 100.82 |
| Group 8 | 100 | 101.72 | 84.62 | 84.82 | 100.05 | 98.59 |
| Mean | 100 | 104.01 | 99.89 | 101.70 | 94.91 | 94.37 |
| S.E.M | 0 | 2.37 | 4.31 | 4.00 | 3.62 | 3.43 |

Table 1.4 : 72 hr of incubation

| | Control | 0.01 μ M | 0.05 μ M | 0.1 μ M | 0.5 μ M | 1 μ M |
|---------|---------|--------------|--------------|-------------|-------------|-----------|
| Group 1 | 100 | 105.15 | 104.07 | 113.28 | 80.94 | 67.03 |
| Group 2 | 100 | 107.32 | 111.65 | 113.09 | 86.54 | 64.14 |
| Group 3 | 100 | 98.64 | 100.63 | 109.12 | 82.75 | 74.25 |
| Group 4 | 100 | 96.66 | 84.01 | 111.83 | 82.93 | 72.81 |
| Group 5 | 100 | 103.04 | 94.39 | 112.79 | 87.58 | 72.13 |
| Group 6 | 100 | 100.28 | 105.24 | 99.36 | 80.04 | 66.05 |
| Group 7 | 100 | 113.34 | 100.46 | 104.51 | 93.84 | 64.77 |
| Group 8 | 100 | 104.69 | 96.59 | 112.97 | 86.29 | 68.74 |
| Mean | 100 | 103.64 | 99.63 | 109.62 | 85.11 | 68.74 |
| S.E.M | 0 | 1.87 | 2.92 | 1.81 | 1.58 | 1.37 |

2. Effects of geldanamycin on LDH release in cultured cerebellar granule neurons

Table 2.1 : 12 hr of incubation

| | Control | 0.01 μ M | 0.05 μ M | 0.1 μ M | 0.5 μ M | 1 μ M |
|---------|---------|--------------|--------------|-------------|-------------|-----------|
| Group 1 | 100 | 94.80 | 90.79 | 107.89 | 103.01 | 113.34 |
| Group 2 | 100 | 102.42 | 85.69 | 106.15 | 105.47 | 121.10 |
| Group 3 | 100 | 85.93 | 91.07 | 101.69 | 101.56 | 108.80 |
| Group 4 | 100 | 83.18 | 95.87 | 103.95 | 107.39 | 110.59 |
| Group 5 | 100 | 98.73 | 98.28 | 100.02 | 105.07 | 102.61 |
| Group 6 | 100 | 100.87 | 100.82 | 100.98 | 103.65 | 111.05 |
| Group 7 | 100 | 101.91 | 97.66 | 100.33 | 102.60 | 103.37 |
| Group 8 | 100 | 87.29 | 93.89 | 107.81 | 109.02 | 119.04 |
| Mean | 100 | 94.39 | 94.26 | 103.60 | 104.72 | 111.24 |
| S.E.M | 0 | 2.77 | 1.74 | 1.17 | 0.89 | 2.33 |

Table 2.2 : 24 hr of incubation

| | Control | 0.01 μ M | 0.05 μ M | 0.1 μ M | 0.5 μ M | 1 μ M |
|---------|---------|--------------|--------------|-------------|-------------|-----------|
| Group 1 | 100 | 98.66 | 105.47 | 117.25 | 118.04 | 138.41 |
| Group 2 | 100 | 93.49 | 105.66 | 114.49 | 120.88 | 128.16 |
| Group 3 | 100 | 101.32 | 96.60 | 99.70 | 117.98 | 125.85 |
| Group 4 | 100 | 97.33 | 99.41 | 98.95 | 108.83 | 120.07 |
| Group 5 | 100 | 93.33 | 104.47 | 91.81 | 104.72 | 106.98 |
| Group 6 | 100 | 101.32 | 97.88 | 100.27 | 127.93 | 103.77 |
| Group 7 | 100 | 97.59 | 98.59 | 98.52 | 133.48 | 128.16 |
| Group 8 | 100 | 95.45 | 102.57 | 96.11 | 116.79 | 107.00 |
| Mean | 100 | 97.31 | 101.33 | 102.14 | 118.58 | 119.80 |
| S.E.M | 0 | 1.10 | 1.29 | 3.15 | 3.29 | 4.45 |

Table 2.3 : 48 hr of incubation

| | Control | 0.01 μ M | 0.05 μ M | 0.1 μ M | 0.5 μ M | 1 μ M |
|---------|---------|--------------|--------------|-------------|-------------|-----------|
| Group 1 | 100 | 102.25 | 98.89 | 103.32 | 119.82 | 120.39 |
| Group 2 | 100 | 93.41 | 96.17 | 102.33 | 120.87 | 117.93 |
| Group 3 | 100 | 96.71 | 107.39 | 114.91 | 129.96 | 124.99 |
| Group 4 | 100 | 91.96 | 104.67 | 121.36 | 120.80 | 122.30 |
| Group 5 | 100 | 96.99 | 103.07 | 113.13 | 123.39 | 114.05 |
| Group 6 | 100 | 101.85 | 108.26 | 123.16 | 114.61 | 125.03 |
| Group 7 | 100 | 109.10 | 112.45 | 116.69 | 122.23 | 126.90 |
| Group 8 | 100 | 101.74 | 105.40 | 116.58 | 122.71 | 127.28 |
| Mean | 100 | 99.25 | 104.54 | 113.94 | 121.79 | 122.26 |
| S.E.M | 0 | 1.97 | 1.84 | 2.69 | 1.51 | 1.64 |

Table 2.4 : 72 hr of incubation

| | Control | 0.01 μ M | 0.05 μ M | 0.1 μ M | 0.5 μ M | 1 μ M |
|---------|---------|--------------|--------------|-------------|-------------|-----------|
| Group 1 | 100 | 97.59 | 117.67 | 113.18 | 117.82 | 145.36 |
| Group 2 | 100 | 110.88 | 115.69 | 113.73 | 129.64 | 144.17 |
| Group 3 | 100 | 106.69 | 121.86 | 128.16 | 129.81 | 149.03 |
| Group 4 | 100 | 105.30 | 123.95 | 122.74 | 125.57 | 148.68 |
| Group 5 | 100 | 101.95 | 113.80 | 122.82 | 122.20 | 143.63 |
| Group 6 | 100 | 99.86 | 108.75 | 131.32 | 118.17 | 157.89 |
| Group 7 | 100 | 95.35 | 113.14 | 119.33 | 121.89 | 123.75 |
| Group 8 | 100 | 99.21 | 104.76 | 114.54 | 131.56 | 124.28 |
| Mean | 100 | 102.10 | 114.95 | 120.73 | 124.58 | 142.09 |
| S.E.M | 0 | 1.83 | 2.25 | 2.39 | 1.90 | 4.25 |

จุฬาลงกรณ์มหาวิทยาลัย

3. Time course of low K^+ -induced injuries in cultured cerebellar granule neurons

Table 3.1 : MTT reduction assay

| | Control | 6 hr | 12 hr | 18 hr | 24 hr | 36 hr | 48 hr |
|----------|---------|--------|-------|-------|-------|-------|-------|
| Group 1 | 100 | 103.06 | 83.59 | 79.82 | 53.26 | 72.38 | 34.36 |
| Group 2 | 100 | 99.19 | 77.37 | 89.48 | 46.47 | 51.17 | 36.23 |
| Group 3 | 100 | 97.34 | 71.48 | 76.80 | 43.59 | 41.92 | 40.29 |
| Group 4 | 100 | 106.81 | 70.14 | 75.29 | 52.69 | 50.29 | 39.88 |
| Group 5 | 100 | 105.76 | 94.04 | 88.38 | 45.59 | 47.23 | 33.11 |
| Group 6 | 100 | 103.04 | 77.65 | 75.00 | 47.59 | 41.01 | 40.37 |
| Group 7 | 100 | 97.18 | 82.38 | 73.62 | 47.86 | 47.19 | 35.28 |
| Group 8 | 100 | 95.99 | 85.99 | 68.42 | 41.09 | 40.23 | 41.51 |
| Group 9 | 100 | 109.14 | 82.23 | 77.41 | 52.09 | 40.76 | 36.87 |
| Group 10 | 100 | 98.85 | 84.65 | 83.93 | 48.84 | 49.31 | 34.71 |
| Group 11 | 100 | 98.40 | 79.00 | 74.31 | 52.52 | 51.19 | 40.92 |
| Group 12 | 100 | 103.84 | 83.33 | 77.73 | 57.26 | 50.15 | 37.71 |
| Mean | 100 | 101.55 | 80.99 | 78.35 | 49.07 | 46.07 | 37.60 |
| S.E.M | 0 | 1.24 | 1.87 | 1.78 | 1.33 | 1.29 | 0.84 |

Table 3.2 : LDH release assay

| | Control | 6 hr | 12 hr | 18 hr | 24 hr | 36 hr | 48 hr |
|----------|---------|--------|--------|--------|--------|--------|--------|
| Group 1 | 100 | 92.64 | 113.85 | 132.60 | 145.72 | 174.67 | 236.35 |
| Group 2 | 100 | 97.76 | 116.26 | 138.95 | 165.58 | 176.28 | 228.82 |
| Group 3 | 100 | 92.81 | 113.21 | 128.89 | 167.62 | 176.99 | 237.75 |
| Group 4 | 100 | 99.53 | 110.68 | 124.37 | 147.47 | 200.23 | 247.29 |
| Group 5 | 100 | 105.88 | 113.64 | 137.78 | 141.63 | 185.69 | 244.69 |
| Group 6 | 100 | 108.13 | 118.49 | 122.46 | 145.59 | 183.26 | 246.86 |
| Group 7 | 100 | 97.07 | 114.39 | 133.79 | 149.73 | 186.08 | 238.77 |
| Group 8 | 100 | 102.65 | 114.71 | 138.40 | 164.31 | 184.47 | 238.77 |
| Group 9 | 100 | 101.00 | 113.40 | 130.79 | 153.13 | 195.53 | 243.11 |
| Group 10 | 100 | 93.86 | 114.05 | 135.82 | 149.24 | 187.72 | 241.66 |
| Group 11 | 100 | 103.24 | 119.96 | 122.24 | 163.59 | 193.53 | 254.07 |
| Group 12 | 100 | 104.05 | 112.95 | 128.51 | 150.63 | 188.35 | 243.80 |
| Mean | 100 | 99.89 | 114.63 | 131.22 | 153.69 | 186.07 | 241.83 |
| S.E.M | 0 | 1.49 | 0.73 | 1.74 | 2.62 | 2.26 | 1.85 |

4. Effects of geldanamycin on low potassium-induced injuries in cultured cerebellar granule neurons. Determined by MTT reduction assay.

Table 4.1 : Cotreatment

| | Control | Low K ⁺ | Trolox | 0.01 μM | 0.025 μM | 0.05 μM | 0.075 μM | 0.1 μM |
|---------|---------|--------------------|--------|------------|-------------|------------|-------------|-----------|
| Group 1 | 100 | 52.72 | 59.51 | 52.45 | 51.56 | 65.08 | 59.65 | 59.58 |
| Group 2 | 100 | 61.96 | 60.68 | 49.87 | 50.54 | 53.13 | 57.20 | 67.26 |
| Group 3 | 100 | 66.38 | 62.66 | 61.87 | 50.21 | 53.95 | 62.85 | 63.35 |
| Group 4 | 100 | 61.16 | 82.54 | 62.36 | 52.12 | 54.17 | 54.80 | 62.66 |
| Group 5 | 100 | 67.41 | 46.31 | 51.40 | 52.45 | 60.00 | 54.97 | 59.96 |
| Group 6 | 100 | 60.28 | 49.74 | 52.24 | 50.84 | 57.62 | 56.92 | 60.03 |
| Group 7 | 100 | 55.46 | 64.43 | 51.16 | 55.71 | 67.37 | 53.99 | 64.20 |
| Group 8 | 100 | 66.92 | 55.21 | 62.11 | 59.72 | 54.89 | 60.03 | 65.95 |
| Mean | 100 | 61.54 | 60.14 | 55.43 | 52.89 | 58.28 | 57.55 | 62.87 |
| S.E.M | 0 | 1.91 | 3.89 | 1.98 | 1.15 | 1.92 | 1.09 | 1.02 |

Table 4.2 : Pretreatment with GA for 6 hr of incubation

| | Control | Low K ⁺ | Trolox | 0.01 μM | 0.025 μM | 0.05 μM | 0.075 μM | 0.1 μM |
|---------|---------|--------------------|--------|------------|-------------|------------|-------------|-----------|
| Group 1 | 100 | 60.80 | 69.02 | 65.68 | 70.37 | 78.34 | 86.51 | 84.38 |
| Group 2 | 100 | 71.98 | 67.29 | 70.89 | 72.24 | 77.63 | 86.18 | 86.05 |
| Group 3 | 100 | 64.34 | 66.32 | 73.39 | 73.99 | 80.83 | 86.86 | 88.47 |
| Group 4 | 100 | 72.39 | 64.51 | 70.24 | 71.85 | 80.43 | 90.42 | 89.41 |
| Group 5 | 100 | 64.47 | 59.46 | 75.53 | 73.22 | 83.03 | 86.84 | 89.47 |
| Group 6 | 100 | 76.97 | 53.63 | 71.84 | 71.05 | 80.79 | 87.30 | 88.62 |
| Group 7 | 100 | 69.91 | 56.37 | 78.21 | 77.19 | 83.07 | 94.13 | 95.75 |
| Group 8 | 100 | 54.82 | 61.33 | 73.14 | 73.28 | 86.87 | 91.50 | 91.64 |
| Mean | 100 | 66.96 | 62.24 | 72.37 | 72.89 | 81.37 | 88.72 | 89.22 |
| S.E.M | 0 | 2.54 | 1.94 | 1.32 | 0.75 | 1.04 | 1.04 | 1.22 |

Table 4.3 : Pretreatment with GA for 12 hr of incubation

| | Control | Low K ⁺ | Trolox | 0.01 μM | 0.025 μM | 0.05 μM | 0.075 μM | 0.1 μM |
|---------|---------|--------------------|--------|------------|-------------|------------|-------------|-----------|
| Group 1 | 100 | 73.57 | 68.52 | 81.16 | 81.89 | 92.50 | 95.76 | 98.61 |
| Group 2 | 100 | 77.65 | 57.40 | 77.57 | 80.02 | 90.70 | 94.54 | 102.94 |
| Group 3 | 100 | 53.25 | 66.23 | 67.89 | 72.56 | 87.57 | 95.19 | 94.01 |
| Group 4 | 100 | 68.49 | 71.18 | 67.61 | 66.72 | 81.66 | 86.39 | 87.43 |
| Group 5 | 100 | 63.80 | 50.72 | 73.70 | 78.08 | 92.53 | 98.54 | 92.29 |
| Group 6 | 100 | 70.45 | 53.54 | 73.21 | 75.24 | 93.1 | 101.85 | 100.32 |
| Group 7 | 100 | 75.85 | 56.66 | 76.73 | 79.71 | 91.22 | 97.81 | 111.27 |
| Group 8 | 100 | 78.90 | 50.26 | 77.54 | 78.90 | 92.59 | 103.86 | 106.92 |
| Mean | 100 | 70.25 | 59.31 | 74.43 | 76.64 | 90.23 | 96.74 | 99.22 |
| S.E.M | 0 | 3.01 | 2.91 | 1.69 | 1.76 | 1.38 | 1.87 | 2.78 |

Table 4.4 : Pretreatment with GA for 24 hr of incubation

| | Control | Low K ⁺ | Trolox | 0.01 μM | 0.025 μM | 0.05 μM | 0.075 μM | 0.1 μM |
|---------|---------|--------------------|--------|------------|-------------|------------|-------------|-----------|
| Group 1 | 100 | 92.29 | 66.94 | 62.19 | 87.90 | 115.93 | 129.84 | 129.84 |
| Group 2 | 100 | 60.88 | 81.24 | 66.03 | 90.93 | 109.27 | 121.57 | 126.92 |
| Group 3 | 100 | 62.03 | 68.89 | 66.98 | 101.43 | 127.59 | 134.55 | 133.01 |
| Group 4 | 100 | 57.39 | 69.44 | 67.75 | 100.33 | 122.29 | 135.10 | 141.06 |
| Group 5 | 100 | 64.17 | 57.14 | 66.34 | 84.06 | 114.96 | 114.76 | 127.56 |
| Group 6 | 100 | 51.57 | 43.69 | 63.19 | 87.99 | 108.46 | 111.61 | 125.98 |
| Group 7 | 100 | 51.07 | 62.47 | 52.99 | 81.45 | 120.52 | 119.76 | 126.18 |
| Group 8 | 100 | 52.14 | 44.69 | 63.03 | 92.95 | 123.08 | 123.82 | 125.54 |
| Mean | 100 | 57.69 | 61.81 | 63.56 | 90.88 | 117.76 | 123.87 | 129.51 |
| S.E.M | 0 | 1.91 | 4.54 | 1.67 | 2.53 | 2.40 | 3.08 | 1.87 |

Table 4.5 : Pretreatment with GA for 48 hr of incubation

| | Control | Low K ⁺ | Trolox | 0.01 μM | 0.025 μM | 0.05 μM | 0.075 μM | 0.1 μM |
|---------|---------|--------------------|--------|------------|-------------|------------|-------------|-----------|
| Group 1 | 100 | 40.42 | 78.58 | 92.20 | 100.00 | 108.89 | 114.25 | 117.97 |
| Group 2 | 100 | 40.99 | 76.69 | 90.38 | 96.28 | 108.26 | 113.16 | 119.06 |
| Group 3 | 100 | 41.95 | 83.57 | 88.03 | 96.93 | 112.06 | 117.72 | 122.41 |
| Group 4 | 100 | 45.54 | 88.27 | 88.19 | 98.95 | 112.46 | 117.39 | 121.68 |
| Group 5 | 100 | 51.11 | 51.95 | 96.49 | 104.61 | 119.74 | 124.63 | 123.80 |
| Group 6 | 100 | 43.46 | 53.13 | 96.86 | 102.12 | 118.91 | 127.68 | 124.63 |
| Group 7 | 100 | 40.93 | 62.76 | 92.90 | 109.26 | 112.76 | 133.34 | 129.12 |
| Group 8 | 100 | 42.14 | 70.70 | 93.83 | 105.35 | 115.95 | 128.81 | 129.01 |
| Mean | 100 | 43.32 | 70.71 | 92.36 | 101.69 | 113.63 | 122.12 | 123.46 |
| S.E.M | 0 | 1.26 | 4.81 | 1.19 | 1.59 | 1.50 | 2.65 | 1.45 |

Table 4.6 : Pretreatment with GA for 72 hr of incubation

| | Control | Low K ⁺ | Trolox | 0.01 μM | 0.025 μM | 0.05 μM | 0.075 μM | 0.1 μM |
|---------|---------|--------------------|--------|------------|-------------|------------|-------------|-----------|
| Group 1 | 100 | 68.88 | 65.07 | 83.48 | 93.85 | 105.63 | 109.26 | 112.59 |
| Group 2 | 100 | 59.35 | 78.81 | 83.85 | 92.74 | 107.04 | 121.67 | 108.30 |
| Group 3 | 100 | 44.77 | 75.26 | 93.03 | 110.91 | 122.67 | 123.45 | 131.66 |
| Group 4 | 100 | 57.56 | 58.80 | 94.35 | 104.55 | 120.74 | 108.81 | 136.15 |
| Group 5 | 100 | 65.18 | 68.22 | 85.74 | 97.59 | 102.40 | 106.11 | 108.95 |
| Group 6 | 100 | 58.29 | 66.80 | 82.24 | 97.38 | 101.75 | 115.93 | 108.29 |
| Group 7 | 100 | 60.12 | 64.37 | 91.38 | 102.67 | 114.63 | 116.64 | 127.31 |
| Group 8 | 100 | 57.28 | 50.77 | 87.27 | 100.65 | 116.86 | 112.15 | 131.56 |
| Mean | 100 | 58.55 | 66.01 | 87.67 | 100.04 | 111.47 | 114.25 | 120.60 |
| S.E.M | 0 | 2.29 | 3.11 | 1.65 | 2.11 | 2.93 | 2.21 | 4.29 |

5. Effects of geldanamycin on low potassium-induced injuries in cultured cerebellar granule neurons. Determined by LDH release assay.

Table 5.1 : Cotreatment

| | Control | Low K ⁺ | Trolox | 0.01 μM | 0.025 μM | 0.05 μM | 0.075 μM | 0.1 μM |
|---------|---------|--------------------|--------|------------|-------------|------------|-------------|-----------|
| Group 1 | 100 | 176.59 | 133.24 | 135.83 | 124.51 | 123.13 | 141.50 | 132.57 |
| Group 2 | 100 | 193.37 | 130.87 | 131.78 | 129.17 | 120.44 | 133.49 | 142.36 |
| Group 3 | 100 | 178.61 | 168.94 | 134.02 | 134.29 | 122.62 | 149.41 | 133.12 |
| Group 4 | 100 | 176.58 | 176.21 | 132.63 | 124.81 | 130.77 | 149.27 | 136.75 |
| Group 5 | 100 | 192.88 | 148.84 | 136.78 | 137.99 | 135.55 | 150.93 | 134.16 |
| Group 6 | 100 | 161.65 | 124.44 | 133.91 | 146.42 | 127.84 | 148.89 | 147.82 |
| Group 7 | 100 | 155.76 | 121.42 | 135.35 | 135.62 | 121.78 | 135.99 | 137.47 |
| Group 8 | 100 | 196.49 | 144.86 | 133.32 | 126.83 | 126.69 | 139.00 | 134.93 |
| Mean | 100 | 178.99 | 143.60 | 134.20 | 132.46 | 126.10 | 143.56 | 137.39 |
| S.E.M | 0 | 5.27 | 7.15 | 0.59 | 2.68 | 1.82 | 2.44 | 1.85 |

Table 5.2 : Pretreatment with GA for 6 hr of incubation

| | Control | Low K ⁺ | Trolox | 0.01 μM | 0.025 μM | 0.05 μM | 0.075 μM | 0.1 μM |
|---------|---------|--------------------|--------|------------|-------------|------------|-------------|-----------|
| Group 1 | 100 | 136.67 | 108.04 | 105.19 | 106.22 | 89.65 | 87.61 | 85.61 |
| Group 2 | 100 | 141.07 | 105.63 | 107.48 | 110.58 | 100.97 | 88.87 | 85.68 |
| Group 3 | 100 | 142.16 | 106.24 | 117.03 | 108.45 | 108.18 | 98.47 | 84.45 |
| Group 4 | 100 | 137.53 | 111.13 | 117.69 | 103.65 | 103.65 | 96.28 | 89.15 |
| Group 5 | 100 | 125.81 | 131.38 | 100.79 | 101.97 | 98.20 | 92.89 | 75.71 |
| Group 6 | 100 | 137.53 | 130.38 | 101.03 | 104.56 | 95.44 | 89.95 | 87.47 |
| Group 7 | 100 | 125.94 | 124.50 | 113.45 | 112.87 | 108.08 | 101.67 | 88.97 |
| Group 8 | 100 | 148.23 | 118.63 | 108.19 | 104.20 | 92.85 | 92.40 | 87.24 |
| Mean | 100 | 136.87 | 119.49 | 108.86 | 106.56 | 99.63 | 93.52 | 85.54 |
| S.E.M | 0 | 2.73 | 3.59 | 2.34 | 1.33 | 2.42 | 1.74 | 1.52 |

Table 5.3 : Pretreatment with GA for 12 hr of incubation

| | Control | Low K ⁺ | Trolox | 0.01 μM | 0.025 μM | 0.05 μM | 0.075 μM | 0.1 μM |
|---------|---------|--------------------|--------|------------|-------------|------------|-------------|-----------|
| Group 1 | 100 | 155.24 | 158.04 | 151.31 | 149.86 | 129.19 | 116.99 | 105.31 |
| Group 2 | 100 | 173.38 | 185.14 | 149.12 | 151.49 | 130.28 | 115.32 | 105.71 |
| Group 3 | 100 | 162.99 | 183.80 | 150.75 | 156.28 | 132.98 | 116.79 | 101.41 |
| Group 4 | 100 | 192.19 | 141.49 | 151.88 | 153.44 | 136.25 | 118.66 | 111.31 |
| Group 5 | 100 | 171.43 | 160.07 | 144.19 | 142.95 | 127.54 | 106.92 | 109.53 |
| Group 6 | 100 | 156.48 | 124.93 | 139.82 | 156.48 | 126.52 | 107.99 | 106.78 |
| Group 7 | 100 | 156.27 | 123.15 | 155.68 | 158.97 | 113.32 | 109.56 | 106.35 |
| Group 8 | 100 | 175.71 | 145.04 | 151.17 | 146.25 | 123.15 | 119.42 | 100.77 |
| Mean | 100 | 167.96 | 152.71 | 149.24 | 151.97 | 127.40 | 113.96 | 105.89 |
| S.E.M | 0 | 4.52 | 8.38 | 1.76 | 1.93 | 2.46 | 1.77 | 1.27 |

Table 5.4 : Pretreatment with GA for 24 hr of incubation

| | Control | Low K ⁺ | Trolox | 0.01 μM | 0.025 μM | 0.05 μM | 0.075 μM | 0.1 μM |
|---------|---------|--------------------|--------|------------|-------------|------------|-------------|-----------|
| Group 1 | 100 | 129.34 | 172.57 | 120.64 | 84.23 | 80.26 | 74.82 | 72.54 |
| Group 2 | 100 | 137.41 | 112.06 | 125.63 | 84.38 | 84.45 | 90.04 | 74.38 |
| Group 3 | 100 | 194.56 | 133.11 | 122.09 | 91.49 | 79.36 | 84.23 | 69.66 |
| Group 4 | 100 | 143.91 | 174.6 | 127.55 | 98.53 | 86.19 | 73.10 | 67.33 |
| Group 5 | 100 | 131.21 | 177.68 | 128.39 | 83.33 | 84.87 | 78.10 | 70.35 |
| Group 6 | 100 | 139.30 | 112.95 | 124.83 | 83.14 | 87.19 | 91.90 | 68.06 |
| Group 7 | 100 | 175.20 | 134.84 | 123.13 | 90.98 | 82.35 | 79.83 | 65.48 |
| Group 8 | 100 | 183.72 | 170.82 | 135.54 | 90.94 | 75.31 | 82.42 | 72.37 |
| Mean | 100 | 154.33 | 148.58 | 125.98 | 88.38 | 82.49 | 81.81 | 70.02 |
| S.E.M | 0 | 9.16 | 10.02 | 1.65 | 1.95 | 1.41 | 2.38 | 1.06 |

Table 5.5 : Pretreatment with GA for 48 hr of incubation

| | Control | Low K ⁺ | Trolox | 0.01 μM | 0.025 μM | 0.05 μM | 0.075 μM | 0.1 μM |
|---------|---------|--------------------|--------|------------|-------------|------------|-------------|-----------|
| Group 1 | 100 | 159.60 | 153.87 | 152.47 | 128.53 | 109.83 | 112.32 | 95.21 |
| Group 2 | 100 | 162.95 | 145.69 | 153.92 | 126.08 | 104.69 | 93.77 | 99.65 |
| Group 3 | 100 | 147.08 | 140.69 | 142.33 | 126.58 | 107.75 | 94.35 | 101.69 |
| Group 4 | 100 | 149.33 | 156.91 | 143.75 | 127.18 | 112.53 | 106.90 | 91.68 |
| Group 5 | 100 | 146.24 | 144.29 | 142.02 | 120.86 | 94.24 | 96.19 | 94.87 |
| Group 6 | 100 | 155.52 | 163.35 | 146.71 | 124.46 | 94.58 | 105.08 | 98.17 |
| Group 7 | 100 | 157.11 | 156.47 | 158.83 | 118.95 | 108.94 | 100.63 | 103.73 |
| Group 8 | 100 | 151.10 | 151.69 | 144.36 | 127.29 | 112.18 | 93.20 | 96.52 |
| Mean | 100 | 153.62 | 151.62 | 148.05 | 124.99 | 105.59 | 100.31 | 97.69 |
| S.E.M | 0 | 2.16 | 2.68 | 2.21 | 1.19 | 2.59 | 2.52 | 1.39 |

Table 5.6 : Pretreatment with GA for 72 hr of incubation

| | Control | Low K ⁺ | Trolox | 0.01 μM | 0.025 μM | 0.05 μM | 0.075 μM | 0.1 μM |
|---------|---------|--------------------|--------|------------|-------------|------------|-------------|-----------|
| Group 1 | 100 | 163.79 | 191.64 | 231.24 | 209.54 | 198.55 | 188.11 | 183.59 |
| Group 2 | 100 | 164.66 | 154.20 | 225.44 | 183.56 | 179.63 | 188.50 | 169.61 |
| Group 3 | 100 | 171.79 | 182.93 | 221.75 | 204.65 | 182.06 | 194.86 | 168.54 |
| Group 4 | 100 | 219.09 | 170.43 | 245.02 | 178.07 | 181.95 | 183.27 | 170.74 |
| Group 5 | 100 | 218.20 | 208.68 | 205.11 | 170.89 | 188.61 | 191.73 | 171.78 |
| Group 6 | 100 | 172.29 | 210.44 | 223.78 | 174.11 | 161.31 | 190.36 | 169.59 |
| Group 7 | 100 | 210.24 | 210.93 | 226.66 | 192.43 | 197.97 | 199.12 | 167.37 |
| Group 8 | 100 | 218.87 | 155.95 | 227.91 | 182.14 | 177.87 | 182.29 | 156.08 |
| Mean | 100 | 192.37 | 185.65 | 225.86 | 186.92 | 183.49 | 189.78 | 169.66 |
| S.E.M | 0 | 9.27 | 8.38 | 3.90 | 4.98 | 4.24 | 1.98 | 2.64 |

6. Effects of trolox on low potassium-induced injuries in cultured cerebellar granule neurons. Determined by MTT reduction assay.

Table 6.1 : Cotreatment

| | Control | Low K ⁺ | 10 μ M | 25 μ M | 50 μ M | 75 μ M | 100 μ M |
|---------|---------|--------------------|------------|------------|------------|------------|-------------|
| Group 1 | 100 | 54.92 | 41.67 | 38.89 | 38.71 | 36.61 | 31.23 |
| Group 2 | 100 | 58.10 | 41.76 | 37.90 | 39.16 | 35.04 | 33.87 |
| Group 3 | 100 | 53.87 | 44.38 | 38.41 | 38.24 | 37.72 | 34.22 |
| Group 4 | 100 | 61.61 | 42.47 | 39.53 | 40.31 | 37.80 | 35.08 |
| Group 5 | 100 | 57.74 | 45.78 | 44.62 | 43.57 | 41.67 | 37.24 |
| Group 6 | 100 | 56.51 | 44.73 | 43.78 | 43.13 | 41.88 | 37.13 |
| Group 7 | 100 | 48.29 | 50.16 | 43.76 | 46.27 | 47.49 | 47.00 |
| Group 8 | 100 | 51.21 | 50.24 | 44.41 | 47.25 | 46.84 | 39.12 |
| Mean | 100 | 55.28 | 45.15 | 41.41 | 42.08 | 40.63 | 36.86 |
| S.E.M | 0 | 1.48 | 1.22 | 1.05 | 1.23 | 1.65 | 1.68 |

Table 6.2 : Pretreatment with trolox for 24 hr of incubation

| | Control | Low K ⁺ | 10 μ M | 25 μ M | 50 μ M | 75 μ M | 100 μ M |
|---------|---------|--------------------|------------|------------|------------|------------|-------------|
| Group 1 | 100 | 60.19 | 63.10 | 62.45 | 66.29 | 58.89 | 54.07 |
| Group 2 | 100 | 61.29 | 62.29 | 68.08 | 67.83 | 69.50 | 63.84 |
| Group 3 | 100 | 59.32 | 68.67 | 70.54 | 64.54 | 76.76 | 66.79 |
| Group 4 | 100 | 61.01 | 58.11 | 58.81 | 56.80 | 57.29 | 54.62 |
| Group 5 | 100 | 59.69 | 58.61 | 60.93 | 58.81 | 69.06 | 62.99 |
| Group 6 | 100 | 56.20 | 63.52 | 66.05 | 62.65 | 74.86 | 67.63 |
| Group 7 | 100 | 51.64 | 59.05 | 66.04 | 69.28 | 67.03 | 68.94 |
| Group 8 | 100 | 48.60 | 62.74 | 60.93 | 71.50 | 66.88 | 68.96 |
| Mean | 100 | 57.24 | 62.01 | 64.23 | 64.71 | 67.53 | 63.48 |
| S.E.M | 0 | 1.67 | 1.22 | 1.44 | 1.79 | 2.41 | 2.14 |

Table 6.3 : Pretreatment with trolox for 48 hr of incubation

| | Control | Low K ⁺ | 10 μ M | 25 μ M | 50 μ M | 75 μ M | 100 μ M |
|---------|---------|--------------------|------------|------------|------------|------------|-------------|
| Group 1 | 100 | 44.62 | 37.82 | 40.77 | 40.38 | 45.51 | 47.69 |
| Group 2 | 100 | 47.69 | 43.72 | 41.41 | 43.61 | 46.67 | 48.46 |
| Group 3 | 100 | 47.75 | 45.50 | 45.29 | 41.65 | 41.86 | 42.39 |
| Group 4 | 100 | 41.11 | 43.79 | 42.93 | 44.86 | 41.44 | 42.83 |
| Group 5 | 100 | 39.67 | 44.48 | 46.63 | 43.25 | 44.68 | 41.51 |
| Group 6 | 100 | 40.49 | 45.19 | 45.81 | 46.83 | 44.38 | 45.19 |
| Group 7 | 100 | 64.09 | 44.84 | 46.08 | 45.29 | 46.79 | 48.20 |
| Group 8 | 100 | 60.49 | 44.65 | 44.11 | 46.06 | 44.53 | 42.74 |
| Mean | 100 | 48.24 | 43.75 | 44.13 | 43.99 | 44.48 | 44.88 |
| S.E.M | 0 | 3.27 | 0.87 | 0.78 | 0.78 | 0.69 | 1.02 |

Table 6.4 : Pretreatment with trolox for 72 hr of incubation

| | Control | Low K ⁺ | 10 μ M | 25 μ M | 50 μ M | 75 μ M | 100 μ M |
|---------|---------|--------------------|------------|------------|------------|------------|-------------|
| Group 1 | 100 | 60.96 | 53.59 | 54.60 | 58.11 | 57.37 | 57.55 |
| Group 2 | 100 | 68.51 | 53.96 | 58.01 | 61.23 | 54.97 | 63.54 |
| Group 3 | 100 | 51.94 | 51.52 | 52.28 | 54.64 | 52.87 | 55.57 |
| Group 4 | 100 | 44.69 | 55.31 | 54.05 | 52.36 | 55.56 | 54.89 |
| Group 5 | 100 | 68.74 | 56.31 | 61.84 | 62.62 | 64.37 | 67.09 |
| Group 6 | 100 | 58.06 | 59.22 | 58.74 | 59.61 | 62.43 | 60.29 |
| Group 7 | 100 | 61.78 | 60.15 | 51.96 | 54.78 | 60.67 | 59.81 |
| Group 8 | 100 | 58.53 | 58.96 | 50.26 | 56.66 | 59.66 | 57.89 |
| Mean | 100 | 59.15 | 56.13 | 55.22 | 57.50 | 58.49 | 59.58 |
| S.E.M | 0 | 2.84 | 1.09 | 1.39 | 1.25 | 1.40 | 1.45 |

7. Effects of trolox on low potassium-induced injuries in cultured cerebellar granule neurons. Determined by LDH release assay.

Table 7.1 : Cotreatment

| | Control | Low K ⁺ | 10 μ M | 25 μ M | 50 μ M | 75 μ M | 100 μ M |
|---------|---------|--------------------|------------|------------|------------|------------|-------------|
| Group 1 | 100 | 148.49 | 171.81 | 174.19 | 165.45 | 188.38 | 165.69 |
| Group 2 | 100 | 163.02 | 155.39 | 177.89 | 175.80 | 182.61 | 176.29 |
| Group 3 | 100 | 167.53 | 171.13 | 155.58 | 158.89 | 171.33 | 163.61 |
| Group 4 | 100 | 159.56 | 152.48 | 172.49 | 161.47 | 164.82 | 170.02 |
| Group 5 | 100 | 155.76 | 177.63 | 169.51 | 155.69 | 165.84 | 158.97 |
| Group 6 | 100 | 158.01 | 181.74 | 163.23 | 162.07 | 159.65 | 177.58 |
| Group 7 | 100 | 165.28 | 166.13 | 161.78 | 164.29 | 171.35 | 181.78 |
| Group 8 | 100 | 163.55 | 181.06 | 185.07 | 175.21 | 168.83 | 144.62 |
| Mean | 100 | 160.15 | 169.67 | 169.97 | 164.86 | 171.60 | 167.32 |
| S.E.M | 0 | 2.16 | 3.91 | 3.37 | 2.56 | 3.36 | 4.23 |

Table 7.2 : Pretreatment with trolox for 24 hr of incubation

| | Control | Low K ⁺ | 10 μ M | 25 μ M | 50 μ M | 75 μ M | 100 μ M |
|---------|---------|--------------------|------------|------------|------------|------------|-------------|
| Group 1 | 100 | 139.20 | 126.36 | 121.18 | 123.60 | 122.29 | 123.16 |
| Group 2 | 100 | 131.87 | 125.19 | 120.17 | 126.93 | 130.25 | 125.94 |
| Group 3 | 100 | 137.38 | 105.05 | 119.96 | 117.01 | 124.11 | 134.45 |
| Group 4 | 100 | 123.29 | 125.89 | 131.53 | 129.83 | 123.49 | 119.09 |
| Group 5 | 100 | 121.72 | 127.23 | 124.76 | 122.64 | 142.48 | 130.36 |
| Group 6 | 100 | 125.36 | 134.28 | 127.13 | 118.94 | 130.29 | 126.92 |
| Group 7 | 100 | 127.10 | 129.47 | 130.03 | 130.55 | 123.33 | 122.49 |
| Group 8 | 100 | 138.29 | 126.56 | 139.54 | 126.03 | 121.49 | 129.99 |
| Mean | 100 | 130.53 | 125.01 | 126.79 | 124.44 | 127.22 | 126.55 |
| S.E.M | 0 | 2.51 | 3.03 | 2.39 | 1.71 | 2.48 | 1.76 |

Table 7.3 : Pretreatment with trolox for 48 hr of incubation

| | Control | Low K ⁺ | 10 μ M | 25 μ M | 50 μ M | 75 μ M | 100 μ M |
|---------|---------|--------------------|------------|------------|------------|------------|-------------|
| Group 1 | 100 | 273.26 | 204.60 | 202.34 | 198.38 | 198.96 | 200.75 |
| Group 2 | 100 | 270.04 | 198.56 | 203.15 | 195.45 | 199.75 | 203.29 |
| Group 3 | 100 | 221.02 | 205.10 | 199.83 | 185.47 | 202.44 | 193.38 |
| Group 4 | 100 | 203.42 | 195.69 | 205.23 | 198.31 | 198.21 | 198.66 |
| Group 5 | 100 | 196.12 | 191.36 | 199.26 | 190.14 | 194.05 | 200.94 |
| Group 6 | 100 | 205.08 | 178.71 | 189.80 | 197.00 | 188.49 | 201.18 |
| Group 7 | 100 | 223.63 | 191.20 | 191.73 | 189.83 | 205.93 | 183.95 |
| Group 8 | 100 | 226.13 | 195.27 | 194.46 | 192.62 | 190.64 | 190.00 |
| Mean | 100 | 227.34 | 195.06 | 198.23 | 193.40 | 197.31 | 196.52 |
| S.E.M | 0 | 10.37 | 2.99 | 1.99 | 1.65 | 2.08 | 2.39 |

Table 7.4 : Pretreatment with trolox for 72 hr of incubation

| | Control | Low K ⁺ | 10 μ M | 25 μ M | 50 μ M | 75 μ M | 100 μ M |
|---------|---------|--------------------|------------|------------|------------|------------|-------------|
| Group 1 | 100 | 279.38 | 269.17 | 245.23 | 224.83 | 256.76 | 246.01 |
| Group 2 | 100 | 256.65 | 273.94 | 330.71 | 317.29 | 271.72 | 262.31 |
| Group 3 | 100 | 202.33 | 282.48 | 282.37 | 257.64 | 262.97 | 254.44 |
| Group 4 | 100 | 319.14 | 255.98 | 288.24 | 252.99 | 275.83 | 270.51 |
| Group 5 | 100 | 287.94 | 261.99 | 266.44 | 295.28 | 301.83 | 286.50 |
| Group 6 | 100 | 266.13 | 271.55 | 339.97 | 287.54 | 298.68 | 314.55 |
| Group 7 | 100 | 260.60 | 301.17 | 283.87 | 318.88 | 300.26 | 269.33 |
| Group 8 | 100 | 242.46 | 289.38 | 297.37 | 319.92 | 310.87 | 295.68 |
| Mean | 100 | 264.33 | 275.71 | 291.78 | 284.29 | 284.87 | 274.92 |
| S.E.M | 0 | 12.09 | 5.21 | 11.05 | 12.62 | 7.22 | 8.02 |

Table 8. Effects of pretreatment with geldanamycin and trolox on glutathione level in low potassium-medium on cultured cerebellar granule neurons. Determined by glutathione assay.

| | Control | Low K ⁺ | GA 0.1 μM | GA+ low K ⁺ | Trolox 100 μM | Trolox+ low K ⁺ |
|---------|---------|--------------------|--------------|---------------------------|------------------|-------------------------------|
| Group 1 | 100 | 66.67 | 133.33 | 144.54 | 150.00 | 50.83 |
| Group 2 | 100 | 58.34 | 125 | 137.14 | 133.33 | 59.71 |
| Group 3 | 100 | 49.23 | 123.75 | 131.27 | 150.00 | 66.67 |
| Group 4 | 100 | 68.12 | 124.77 | 139.73 | 166.67 | 71.22 |
| Group 5 | 100 | 66.22 | 128.19 | 133.31 | 166.67 | 72.36 |
| Group 6 | 100 | 63.16 | 119.23 | 130.66 | 166.67 | 81.38 |
| Group 7 | 100 | 50.00 | 109.23 | 124.99 | 150.00 | 84.39 |
| Group 8 | 100 | 66.67 | 125.00 | 140.74 | 150.00 | 78.32 |
| Mean | 100 | 61.05 | 123.56 | 135.29 | 154.17 | 70.61 |
| S.E.M | 0 | 2.72 | 2.49 | 2.26 | 4.17 | 3.99 |

Table 9. Effects of pretreatment with geldanamycin and trolox on low potassium-medium in cultured cerebellar granule neurons. Determined by TBARS assay.

| | Control | Low K ⁺ | GA 0.1 μM | GA+ low K ⁺ | Trolox 100 μM | Trolox+ low K ⁺ |
|---------|---------|--------------------|--------------|---------------------------|------------------|-------------------------------|
| Group 1 | 100 | 115.04 | 79.94 | 98.10 | 48.68 | 82.29 |
| Group 2 | 100 | 138.57 | 69.01 | 107.27 | 48.17 | 82.82 |
| Group 3 | 100 | 133.31 | 56.57 | 101.04 | 55.76 | 89.53 |
| Group 4 | 100 | 117.19 | 79.28 | 88.35 | 51.87 | 81.56 |
| Group 5 | 100 | 149.28 | 78.59 | 96.37 | 60.10 | 90.49 |
| Group 6 | 100 | 135.98 | 78.53 | 83.01 | 74.64 | 89.62 |
| Group 7 | 100 | 133.82 | 83.88 | 88.49 | 61.17 | 80.09 |
| Group 8 | 100 | 122.76 | 88.94 | 77.53 | 70.06 | 79.43 |
| Mean | 100 | 130.74 | 76.84 | 92.52 | 58.81 | 84.48 |
| S.E.M | 0 | 4.10 | 3.51 | 3.49 | 3.43 | 1.63 |

CURRICULUM VITAE

| | |
|----------------------|--|
| NAME | Miss Arunee Kumdee |
| DATE OF BIRTH | 17 April 1974 |
| PLACE OF BIRTH | Kanchanaburi province, Thailand |
| INSTITUTION ATTENDED | Silpakorn University, 1992-1997: Bachelor of Science (Pharmacy) Chulalongkorn University, 2001-2004 Master of Science in Pharmacy (Pharmacology) |
| POSITION & OFFICE | 1997-present, Pharmacy Department Paholpolpayuhasena Hospital, Kanchanaburi, Thailand Position: Pharmacist Tel. (034) 622999 |

สถาบันวิทยบริการ
 จุฬาลงกรณ์มหาวิทยาลัย